

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

**CORRECTED VERSION**

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
16 March 2000 (16.03.2000)

PCT

(10) International Publication Number  
**WO 00/14115 A1**

(51) International Patent Classification<sup>7</sup>: C07K 14/72,  
14/68, G01N 33/566, 33/74, 33/94

(21) International Application Number: PCT/US99/19790

(22) International Filing Date: 30 August 1999 (30.08.1999)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
60/099,104 3 September 1998 (03.09.1998) US

(71) Applicant: MILLENNIUM PHARMACEUTICALS,  
INC. {US/US}: 640 Memorial Drive, Cambridge, MA  
02139 (US).

(72) Inventor: DUMAN, Ronald; Guilford, CT 06437 (US).

(74) Agent: MEIKLEJOHN, Anita, L.; Fish & Richardson  
P.C., 225 Franklin Street, Boston, MA 02110-2804 (US).

(81) Designated States (national): AE, AL, AM, AT, AU, AZ,  
BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE,

ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP,  
KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD,  
MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD,  
SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN,  
YU, ZA, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM,  
KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM,  
AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT,  
BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC,  
NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA,  
GN, GW, ML, MR, NE, SN, TD, TG).

Published:  
— with international search report

(48) Date of publication of this corrected version:  
13 December 2001

(15) Information about Correction:  
see PCT Gazette No. 50/2001 of 13 December 2001, Section II

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*



**WO 00/14115 A1**

(54) Title: MC4-R AS TARGET FOR THE IDENTIFICATION OF COMPOUNDS USED TO TREAT DRUG ADDICTION

(57) Abstract: The present invention relates to drug screening assays and therapeutic methods for the treatment of addictive behavior disorders, such as cocaine and morphine addiction utilizing the melanocortin 4-receptor (MC4-R) as the target for intervention. The invention also relates to compounds that antagonize the activity or expression of the MC4-R, and the use of such compounds in the treatment of addictive behavior disorders.

- 1 -

MC4-R AS TARGET FOR THE IDENTIFICATION OF COMPOUNDS  
USED TO TREAT DRUG ADDICTION

5

Field of the Invention

The present invention is in the field of drug discovery to treat addictive behavior, particularly drug addiction. The present invention specifically provides drug screening assays and therapeutic methods for the 10 treatment of addictive behavior, particularly drug addiction, involving the melanocortin 4-receptor (MC4-R). The invention also provides novel methods of using antagonists of the activity or expression of MC4-R to treat addictive disorders.

15

Background of the Invention

Drug Addiction

It is well known that the chronic administration of opioids, cocaine and other drugs of abuse results in tolerance and, eventually, dependence. The use of 20 cocaine, opiates, and alcohol are extremely widespread in many countries, despite the well known adverse effects of their use. Drug abuse endures as one of the major public health problems in the United States, and throughout the world. One of the core features of addictive disorders, 25 in laboratory animals as well as in humans, is that drugs of abuse are acutely reinforcing and produce intense drug craving following chronic exposure.

Behavioral and pharmacological studies have implicated the mesolimbic dopamine system (containing the 30 ventral tegmental area [VTA] and its projections, e.g., the nucleus accumbens [NAc]) in the acute reinforcement and craving seen with opiates, cocaine, alcohol, and other drugs of abuse. An important goal of research in this area is to identify changes in this neural pathway 35 that are caused by drugs of abuse and account for the intense craving seen with chronic drug use. Another

- 2 -

critical goal is the identification of factors that can inhibit or reverse these changes to the neural pathway.

Over the past several years, studies have identified a series of common and specific actions of 5 opiates, cocaine, and alcohol on the mesolimbic dopamine system (see, Nestler et al., 1993, *Neuron* 11:995-1006). Different classes of neuronal receptors and neurotransmitters in the brain have been implicated in the complex mechanisms underlying, for example, the 10 addictive effects of opiates. Experimental findings suggest that the opioid, dopaminergic, serotonergic, and benzodiazepine receptor subtypes are involved in addictive effects.

In the VTA, the effects of various drugs of abuse 15 include increased levels of tyrosine hydroxylase (TH) and glial fibrillary acidic protein (GFAP), and decreased levels of neurofilaments. In the NAc, the effects include decreased levels of the inhibitory G protein, Gi alpha, and increased levels of adenylyl cyclase and 20 cyclic AMP-dependent protein kinase. Increasing direct evidence now supports a role for these various biochemical adaptations in the behavioral actions of drugs of abuse mediated via the mesolimbic dopamine system. The finding of increased levels of glial 25 filaments, and reduced levels of neurofilaments, in the VTA suggests that a major form of plasticity, perhaps even neural injury, occurs in this brain region during the course of chronic drug exposure. This possibility is further supported by the observation that chronic 30 morphine or cocaine administration reduces axoplasmic transport, specifically from the VTA to the NA.

Physical dependence or drug addiction to drugs such as narcotics or cocaine has been traditionally treated by drug withdrawal through withholding the drug

- 3 -

from the drug dependent individual, gradually decreasing the amount of drug, particularly with opioids, taken by the individual over time, administering an antagonistic drug, or substituting another drug, such as methadone, 5 buprenorphine, or methadyl acetate, for the drug to ameliorate the physical need for the drug. When a drug is discontinued, withdrawal symptoms appear, the character and severity of which are dependent upon such factors as the particular drug being withdrawn, the daily 10 dose of the drug that is being withdrawn, the duration of use of the drug, and the health of the drug dependent individual.

It is therefore desirable to identify the biological mechanism of drug addiction, and addictive 15 behavior in general, so that better and more effective therapeutic compounds can be identified. The present invention identifies one of the mechanisms of drug addiction and provides methods of identifying compounds for use in treating drug addiction.

20 Melanocortin Receptors

Melanocortins, products of pro-opiomelanocortin (POMC) post-translational processing, are known to have a broad array of physiological actions. Nakanishi et al., Nature 278:423-427 (1979). Aside from their well known 25 effects on adrenal cortical functions (adrenocorticotrophic hormone, ACTH) and on melanocytes (melanocyte stimulating hormone, MSH), melanocortins have been suggested to affect behavior, learning, memory, control of the cardiovascular system, analgesia, 30 thermoregulation, body weight and the release of other neurohumoral agents including prolactin, luteinizing hormone, and biogenic amines. De Wied et al., Methods Achiev. Exp. Pathol. 15:167-199 (1991); De Wied et al., Physiol. Rev. 62:977-1059 (1982); Gruber et al., Am.

- 4 -

J. Physiol. 257:R681-R694 (1989); Murphy et al.,  
Science 210:1247-1249 (1980); Murphy et al., Science  
221:192-193 (1983); Ellerkmann et al., Endocrinol.  
130:133-138 (1992) and Versteeg et al., Life Sci.  
5 38:835-840 (1986). Peripherally, melanocortins have been  
suggested to have immunomodulatory and neurotrophic  
properties and to be involved in events surrounding  
parturition. Cannon et al., J. Immunol. 137:2232-2236  
(1986); Gispen, Trends Pharm. Sci. 11:221-222 (1992);  
10 Wilson, J. F., Clin. Endocrinol. 17:233-242 (1982);  
Clark et al., Nature 273:163-164 (1978) and Silman et  
al., Nature 260:716-718 (1976). Furthermore,  
melanocortins are present in a myriad of normal human  
tissues including the brain, adrenal, skin, testis,  
15 spleen, kidney, ovary, lung, thyroid, liver, colon, small  
intestine and pancreas. Tatro et al., Endocrinol.  
121:1900-1907 (1987); Mountjoy et al., Science 257:1248-  
1251 (1992); Chhajlani et al., FEBS Lett. 309:417-420  
(1992); Gantz et al. J. Biol. Chem. 268:8246-8250  
20 (1993) and Gants et al., J. Biol. Chem. 268:15174-15179  
(1993).

Recent studies have described a diversity of  
subtypes of receptors for the melanocortin peptides and  
determined that they all belong to the superfamily of  
25 seven transmembrane G-protein linked cell surface  
receptors. Mountjoy et al., Science 257:1248-1251  
(1992); Chhajlani et al., FEBS Lett. 309:417-420 (1992);  
Gantz, Biol. Chem. 268:8246-8250 (1993). In total five  
receptors have been identified by sequence homology to the  
30 first cloned receptor.

The first two melanocortin receptors cloned were  
the melanocyte MSH receptor, MC1-R, and the  
adrenocortical ACTH receptor, MC2-R (Mountjoy, Science  
257:1248-1251 (1992); Chhajlani & Wikberg, FEBS Lett.  
35 309:417-420 (1992)). Subsequently, three additional

- 5 -

melanocortin receptor genes were cloned that recognize the core heptapeptide sequence (MEHFRWG) of melanocortins. Two of these receptors have been shown to be expressed primarily in the brain, MC3-R (Roselli- 5 Rehfuss et al., Proc. Natl. Acad. Sci. USA 90:8856-8860 (1993); Gantz et al., J. Biol. Chem. 268:8246-8250 (1993)) and MC4-R (Gantz et al., J. Biol. Chem. 268:15174-15179 (1993); Mountjoy et al., Mol. Endo. 8:1298-1308 (1994)). A fifth melanocortin receptor (originally 10 called MC2-R) is expressed in numerous peripheral organs as well as the brain (Chhajlani et al., Biochem. Biophys. Res. Commun. 195:866-873 (1993); Gantz et al., Biochem. Biophys. Res. Commun. 200:1214-1220 (1994)). The native 15 ligands and functions of these latter three receptors remains largely unknown.

Recently, the Agouti protein in mice (US Patent No. 5,789,651), and the agouti-related protein in humans (US Patent No. 5,766,877), were shown to be natural ligands for the MC4-R protein. The agouti protein is a 20 secreted protein expressed in hair follicles and the epidermis, the expression of which correlates with the synthesis of the yellow pigment associated with the agouti phenotype (Miller et al., Gene & Development 7:454-467 1993)). Certain dominant mutations of the 25 agouti gene result in de-regulated, ubiquitous expression of the agouti protein in mice, demonstrating pleiotropic effects that include obesity and increased tumor susceptibility. (Miller et al., *supra*, (1993); Michaud et al., Genes & Development 7:1203-1213 (1993)). Ectopic 30 expression of the wild-type agouti protein in transgenic mice results in obesity, diabetes, and the yellow coat color commonly observed in spontaneous obese mutants (Klebig, et al., Proc. Natl. Acad. Sci. USA 92:4728-4732 (1995)). For reviews, see Jackson, *Nature* 362:587-588 35 (1993); Conklin & Bourne, *Nature* 364:110 (1993);

- 6 -

Siracusa, TIG 10:423-428 (1994); Yen et al., FASEB J. 8:479-488 (1994); Ezzell, J. NIH Res. 6:31-33 (1994); and Manne et al., Proc. Sci. USA 92:4721-4724 (1995). Agouti has been reported to be a competitive antagonist of (MSH 5 binding to the MC1-R and MC4-R in vitro (Lu et al., Nature 371:799-802 (1994)), and the authors speculated that ectopic expression of agouti may lead to obesity by antagonism of melanocortin receptors expressed outside the hair follicle. In this regard, a number of theories 10 have been proposed to account for the induction of obesity by ectopic expression of agouti.

While prior structure-function analyses have been reported in the past on the affinity and potency of the alpha -MSH peptide at the MSH receptor site (for reviews 15 see Peptide Protein Rev 3:1 (1984), The Melanotropic Peptides, Vol. I, II, and III (CRC Press) (1988)), only a few relatively weak antagonists have resulted from these studies [see Int J Peptide Protein Res 35:228 (1990); Peptides 11:351 (1990); and Peptide Res 3:140 (1989)]. 20 However, these papers demonstrate that methods for identifying antagonists of the melanocortin family of receptors is within the skill of the art.

#### Summary of the Invention

The present invention is based on several sets of 25 experiments that includes the observation that mice deficient in the MC4-R protein (MC4-R knockout mice) do not display the addictive effects induced by drugs of addiction, particularly cocaine and morphine. Based on these observations, the present invention provides a 30 novel target for the identification and development of compounds that can be used to treat addictive behavior, particularly drug addiction as well a therapeutic target for treating drug addition.

- 7 -

Specifically, assays are provided (and equivalent assays can be configured) to identify antagonists of the MC4-R receptor protein, in particular receptor binding assays, competition binding assays, activity assays, 5 expression assays (transcription and translation), animal assays and combinations thereof. Such assays result in the identification of compounds that can be used in treating addictive disorders.

It is important to note that assays for 10 identifying antagonists of the MC4-R protein and assays for testing a compound's ability to modulate an addictive behavior in an animal are known in the art.

Brief Description of the Drawings

Figure 1. Deduced amino acid sequences of the 15 melanocortin receptors. The serpentine structure of the melanocortin receptors predicts that the hydrophilic domains located between the TM domains are arranged alternately outside and within the cell to form extracellular domains (ECD; amino acid residues 1-74, 20 137-155, 219-231 and 305-316 in FIG. 1) and cytoplasmic domains (CD; amino acid residues 102-112, 178-197, 251-280 and 339-end in FIG. 1) of the receptor. The predicted transmembrane domains are denoted by overbars and Roman numerals, and the four extracellular domains 25 (ECD1, ECD2, ECD3 and ECD4) and four cytoplasmic domains (CD1, CD2, CD3 and CD4) are indicated.

Figure 2. Regional distribution of MC4-R mRNA expression in the rat brain.

Figure 3. Regional specific expression of MC4-R 30 mRNA in the rat brain

Figure 4. Changes seen in MC4-R mRNA levels in regional centers of the rat brain caused by the administration of cocaine.

- 8 -

Figure 5. Changes seen in MC4-R mRNA levels in the neostriatum of the rat brain caused by the administration of varying doses of morphine.

Figure 6. Changes seen in POMC mRNA levels in 5 regional centers of the rat brain caused by the administration of cocaine.

Figure 7. Changes seen in ( $\alpha$ -MSH-induced grooming behavior in rats caused by the administration of combinations of saline (sal), ( $\alpha$ -MSH, and cocaine (coc).

10 Figure 8. Changes seen in ( $\alpha$ -MSH-Induced locomotor activity in rats caused by the administration of combinations of saline (sal), ( $\alpha$ -MSH, and cocaine (coc).

15 Figure 9. Cocaine (10mg/kg) induced locomotor sensitization in Agouti and C57 mice.

Figure 10. Novelty induced locomotor activity in Agouti and C57 mice.

Figure 11. Cocaine (5mg/kg) induced locomotor sensitization in Agouti and C57 (wild-type) mice.

20 Figure 12. Cocaine (10mg/kg) induced locomotor sensitization in C57 (wild-type) and MC4-R knockout (homozygous) mice.

25 Figure 13. Cocaine (10mg/kg) induced locomotor sensitization in C57 (wild-type) and MC4-R knockout (homozygous) mice.

Figure 14. Baseline locomotor activity in C57 (wild-type) and MC4-R knockout (homozygous and heterozygous) mice.

30 Figure 15. Cocaine (10mg/kg) induced locomotor sensitization in rats treated with and without Intra-Nac infusions of SHU9119 (an antagonist of MC4-R).

Figure 16. Cocaine induced place preference in rats treated with and without Intra-Nac infusions of SHU9119 (an antagonist of MC4-R).

Description of the Preferred EmbodimentsMC4-R and Addiction

Described below are experiments demonstrating that some of the addictive effects of drugs of addiction 5 (e.g., cocaine and morphine) are potentiated, in part, by the activity of the melanocortin-4 receptor (MC4-R). Mice lacking MC4-R (MC4-R knockout mice) do not demonstrate behavioral responses indicative of drug addiction induced to chronic and acute administration of 10 cocaine or morphine. Based on these observations, one aspect of the present invention provides one of the specific molecular mechanisms that mediates addictive behavior.

As described below, this molecular mechanism can 15 be used: 1) to identify and isolate compounds for treating drug addiction; 2) as a target to rationally design compounds for use in treating drug addiction; and 3) as a therapeutic target for treating drug addiction.

Methods To Identify Compounds For Treating Drug Addiction

20 The present invention provides methods for identifying compounds that can be used to treat drug addiction. These methods are based on identifying antagonists of the melanocortin-4 receptor (MC4-R).

In general, three formats used in drug discovery, 25 cell based systems, cell free systems, and animal based systems, can be adapted for use in the present invention. Further, the assays of the present invention can be configured as binding assays, competitive binding assays or activity-based assays. Lastly, a combination of cell 30 free, cell based, and animal based assays can be used.

Specifically, to identify a therapeutic compound for use in treating drug addiction using a cell based binding assay, a cell expressing a MC4-R protein, a cell expressing a fragment of the MC4-R protein, or a cell 35 expressing a protein containing a fragment of the MC4-R

- 10 -

protein as a fusion protein (hereinafter collectively  $\delta$  a cell expressing the MC4-R protein) is incubated in the presence and absence of a compound to be tested. After mixing under conditions that allow association of the 5 MC4-R protein with the compound (if such an interaction will occur), the two mixtures are analyzed and compared to determine if the compound bound to the cell expressing the MC4-R protein. Compounds that bind to cells expressing the MC4-R protein will be identified as a 10 potential antagonist of MC4-R. Preferred potential antagonists do not substantially bind to otherwise identical cells which do not express MC4-R.

To identify a therapeutic compound for use in treating drug addiction using a cell free binding assay, 15 an isolated MC4-R protein, an isolated fragment of the MC4-R protein, or an isolated protein containing a fragment of the MC4-R protein as a fusion protein (hereinafter collectively the MC4-R protein) is incubated in the presence and absence of a compound to be 20 tested. After mixing under conditions that allow association of the MC4-R protein with the compound (if such an interaction will occur), the two mixtures are analyzed and compared to determine if the compound bound to the MC4-R protein. Compounds that bind to the MC4-R 25 protein will be identified as a potential antagonist of MC4-R.

To identify a therapeutic compound for use in treating drug addiction using a cell based competition binding assay, a cell expressing a MC4-R protein, a cell 30 expressing a fragment of the MC4-R protein, or a cell expressing a protein containing a fragment of the MC4-R protein as a fusion protein (hereinafter collectively  $\delta$  a cell expressing the MC4-R protein) is incubated in the presence and absence of a compound to be tested and 35 further in the presence of a ligand of MC4-R. After

- 11 -

mixing under conditions that allow association of the cell expressing the MC4-R protein with the MC4-R ligand, the two mixtures are analyzed and compared to determine if the compound reduced or blocked the binding of the 5 MC4-R ligand to the cell expressing the MC4-R protein. Compounds that reduce or block the binding of the MC4-R ligand to the cell expressing the MC4-R protein will be identified as a potential antagonist of MC4-R.

To identify a therapeutic compound for use in 10 treating drug addiction using a cell-free based competition binding assay, a MC4-R protein, a fragment of the MC4-R protein, or a protein containing a fragment of the MC4-R protein as a fusion protein (hereinafter collectively  $\delta$ a MC4-R protein $\delta$ ) is incubated in the 15 presence and absence of a compound to be tested and further in the presence of a ligand of MC4-R. After mixing under conditions that allow association of the MC4-R protein with the MC4-R ligand, the two mixtures are analyzed and compared to determine if the compound 20 reduced or blocked the binding of the MC4-R ligand to the MC4-R protein. Compounds that reduce or block the binding of the MC4-R ligand to the MC4-R protein will be identified as a potential antagonist of MC4-R.

To identify a therapeutic compound for use in 25 treating drug addiction using a cell based activity assay, a cell expressing a MC4-R protein, a cell expressing a functional fragment of the MC4-R protein, or a cell expressing a protein containing a functional fragment of the MC4-R protein as a fusion protein 30 (hereinafter collectively a cell expressing the MC4-R protein) is incubated in the presence and absence of a compound to be tested. After mixing under conditions that allow association of the MC4-R protein with the compound (if such an interaction will occur), the 35 activity of the MC4-R protein is determined in the two

- 12 -

mixtures and compared to determine if the compound antagonized the MC4-R activity in the cell. Compounds that antagonize the activity of the MC4-R protein will be identified as a potential antagonist of MC4-R for use in 5 treating drug addiction. Such activity assays are best performed in the presence of a ligand of MC4-R.

Each of the methods outlined above will be discussed in greater detail below.

The methods of the present invention are suitable 10 for use in identifying compounds for treating addiction to a wide variety of addictive compounds. Repeated administration to a subject of certain drugs such as cocaine, opiates, alcohol, hallucinogens, minor tranquilizers, nicotine, and stimulants can lead to 15 physical and/or psychological dependence upon that drug or substance. Although almost any drug is capable of addiction, certain drugs demonstrated a marked propensity to become addictive. These include opiates (opium, morphine, heroin, and so called "designer drugs," which 20 are opiates that have been chemically modified to avoid literal violation of the controlled substance laws, or to create a better or different psychophysiological effect), methadone, cocaine, nicotine, alcohol, certain depressants, and certain stimulants. When the drug or 25 substance of abuse is withdrawn from a dependent subject, the subject develops certain symptoms including sleep and mood disturbance and intense craving for the drug or substance of abuse. These symptoms may be collectively described as a withdrawal syndrome in connection with the 30 present invention. As discussed in the Background, many drugs of addiction have been found to stimulate similar behavior centers of the brain. Experimental results described in the Examples (below) demonstrate that two classes of addictive compounds, cocaine and opiates, 35 stimulate similar biological response, e.g. increased

- 13 -

MC4-R expression in the nucleus accumbens and neostriatum. Accordingly, compounds identified in the present methods will be useful in treating addictive behavior to a wide variety of addictive stimulus.

5 As used herein, the term "addictive disease, disorder, behavior or addiction" refers to a disease or disorder in which the subject has an extreme craving or compulsion to repeat a particular behavior. The present invention is particularly directed to therapeutic  
10 treatment of a drug addiction. Notwithstanding the specifically exemplified ability of the present invention to modulate the biochemistry and behavior that correlate with drug abuse, the invention further extends to the treatment of addictive psychological diseases or  
15 disorders, such as, but not limited to, obsessive-compulsive disease.

The methods of the present invention and the compounds identified using the present methods can be used to treat or prevent an addictive disease or disorder  
20 in a subject. Preferably the subject is a human, however, as animals in addition to humans may demonstrate addictive diseases or disorders, whether resulting from addiction to opiates or other drugs subsequent to a veterinary procedure or as a result of a psychological  
25 disorder, such as an obsessive compulsive-type of disorder, the invention can be used in birds, such as chickens, turkeys, and pets; in mammals, including but not limited to domesticated animals (canine and feline); farm animals (bovine, ovine, equine, caprine, porcine,  
30 and the like); rodents; and undomesticated animals.

The MC4-R protein used in the present method can either be the known human MC4-R receptor (Mol. Endocrinol. 8:1298-1308 (1994), US Patent No. 5,703,220, Genbank Accession No. 998457), any allelic variant  
35 thereof (Genbank Accession No. 417280 or 136281), or any

- 14 -

ortholog of the human MC4-R protein, such as, but not limited to mouse MC4-R (Genbank Accession No. 3024117) and rat MC4-R (Genbank Accession No. 2494982). Since members of the MC4-R family of proteins display high 5 levels of sequence homology, most members of this family can be used interchangeably in the present methods.

As indicated above, as an alternative to the entire MC4-R protein, a fragment of the MC4-R protein can be used. Such fragments may be selected based on a 10 function, such as the ligand or G-protein binding domain, or can be randomly generated. Preferred fragments will contain the ligand binding domain of the MC4-R protein.

Alternatively, a fusion protein containing the MC4-R protein, or a fragment thereof, can be used. The 15 use of a fusion protein in compound screening assays is well known in the art since fusion protein can aid in configuring such assays, for example with the use of an IgG fusion protein to aid in immobilization.

The MC4-R used in the present method can be any 20 isolated member of the MC4-R ligand family. Examples of MC4-R ligands include human ( $\alpha$ -MSH (FEBS Lett. 135:97-102 (1981), Science 257:543 (1992), Genbank Accession No. P01189), murine ( $\alpha$ -MSH (FEBS Lett. 156:67-71 (1983), Genbank Accession No. P01193), rat ( $\alpha$ -MSH (FEBS Lett. 25 193:54-58 (1985), Genbank Accession No. P01194), the agouti protein (US Patent No. 5,789,651), and the recently clone agouti related protein from humans (US Patent No. 5,766,877).

The assays described herein are intended to 30 identify compounds that affect MC4-R activity. For example, compounds that affect MC4-R activity include but are not limited to compounds that bind to MC4-R, inhibit binding of a natural ligand, block activation, and compounds that bind to the natural ligand of the MC4-R 35 and reduce ligand activity. Compounds that affect MC4-R

- 15 -

gene activity (by affecting MC4-R gene expression, including molecules, e.g., proteins or small organic molecules, that affect transcription or interfere with splicing events so that expression of the full length or 5 the truncated form of the MC4-R can be antagonized) can also be identified using the screen assays of the invention. However, it should be noted that the screening assays described can also identify compounds that antagonize MC4-R signal transduction (e.g., 10 compounds which affect downstream signaling events, such as inhibitors or enhancers of one or more G protein activities which participate in transducing the signal induced by ligand binding to the MC4-R). The identification and use of compounds that affect signaling 15 events downstream of MC4-R and thus modulate effects of MC4-R on the development of addictive behavior disorders are within the scope of the invention.

The compounds that may be screened in accordance with the assays of the invention include, but are not 20 limited to, peptides, antibodies and fragments thereof, and other small molecules or organic compounds that bind to the MC4-R and inhibit the activity triggered by the natural ligand (i.e., antagonists) and peptides, antibodies or fragments thereof, and other small molecule 25 or organic compound that bind to and "neutralize" the natural ligand.

Compounds may include, but are not limited to, peptides such as, for example, soluble peptides, including but not limited to members of random peptide 30 libraries; (see, e.g., Lam et al., 1991, *Nature* 354:82-84; Houghten et al., 1991, *Nature* 354:84-86), and combinatorial chemistry-derived molecular library made of D- and/or L- configuration amino acids, phosphopeptides (including, but not limited to, members of random or 35 partially degenerate, directed phosphopeptide libraries;

- 16 -

see, e.g., Songyang et al., 1993, Cell 72:767-778), antibodies (including, but not limited to, polyclonal, monoclonal, humanized, anti-idiotypic, chimeric or single chain antibodies, and FAb, F(ab()), and FAb expression library fragments, and epitope-binding fragments thereof), and small organic or inorganic molecules.

Other compounds that can be screened in accordance with the invention include, but are not limited to, small organic molecules that are able to cross the blood-brain barrier, gain entry into an appropriate cell and affect the expression of the MC4-R gene or some other gene involved in the MC4-R signal transduction pathway (e.g., by interacting with the regulatory region or transcription factors involved in gene expression) and compounds that affect the activity of the MC4-R or the activity of some other intracellular factor involved in the MC4-R signal transduction pathway, such as, for example, the MC4-R associated G protein.

Computer modeling and searching technologies permit identification of compounds, or the improvement of already identified compounds, that can antagonize MC4-R expression or activity. Having identified such a compound or composition, the active sites or regions are identified. Such active sites might typically be ligand binding sites. The active site can be identified using methods known in the art including, for example, from the amino acid sequences of peptides, from the nucleotide sequences of nucleic acids, or from study of complexes of the relevant compound or composition with its natural ligand. In the latter case, chemical or X-ray crystallographic methods can be used to find the active site by finding where on the factor the complexed ligand is found.

Next, the three dimensional geometric structure of the active site is determined. This can be done by known

- 17 -

methods, including X-ray crystallography, which can determine a complete molecular structure. On the other hand, solid or liquid phase NMR can be used to determine certain intra-molecular distances. Any other 5 experimental method of structure determination can be used to obtain partial or complete geometric structures. The geometric structures may be measured with a complexed ligand, natural or artificial, which may increase the accuracy of the active site structure determined.

10 If an incomplete or insufficiently accurate structure is determined, the methods of computer based numerical modeling can be used to complete the structure or improve its accuracy. Any recognized modeling method may be used, including parameterized models specific to 15 particular biopolymers such as proteins or nucleic acids, molecular dynamics models based on computing molecular motions, statistical mechanics models based on thermal ensembles, or combined models. For most types of models, standard molecular force fields, representing the forces 20 between constituent atoms and groups, are necessary, and can be selected from force fields known in physical chemistry. The incomplete or less accurate experimental structures can serve as constraints on the complete and more accurate structures computed by these modeling 25 methods.

Finally, having determined the structure of the active site, whether experimentally, by modeling, or by a combination, candidate modulating compounds can be identified by searching databases containing compounds 30 along with information on their molecular structure. Such a search seeks compounds having structures that match the determined active site structure and that interact with the groups defining the active site. Such a search can be manual, but is preferably computer assisted. These

- 18 -

compounds found from this search are potential MC4-R antagonizing compounds.

Alternatively, these methods can be used to identify improved antagonizing compounds from an already 5 known antagonizing compound or ligand. The composition of the known compound can be modified and the structural effects of modification can be determined using the experimental and computer modeling methods described above applied to the new composition. The altered 10 structure is then compared to the active site structure of the compound to determine if an improved fit or interaction results. In this manner systematic variations in composition, such as by varying side groups, can be quickly evaluated to obtain modified 15 modulating compounds or ligands of improved specificity or activity.

Further experimental and computer modeling methods useful to identify modulating compounds based upon identification of the active sites of MC4-R and related 20 transduction and transcription factors will be apparent to those of skill in the art.

Examples of molecular modeling systems are the CHARMM and QUANTA programs (Polygen Corporation, Waltham, MA). CHARMM performs the energy minimization and 25 molecular dynamics functions. QUANTA performs the construction, graphic modeling and analysis of molecular structure. QUANTA allows interactive construction, modification, visualization, and analysis of the behavior of molecules with each other.

30 A number of articles review computer modeling of drugs interactive with specific proteins, such as Rotivinen, et al. (1988, Acta Pharmaceutical Fennica 97:159-166); Ripka (1988 New Scientist 54-57); McKinlay and Rossmann (1989, Annu. Rev. Pharmacol. Toxicol. 35 29:111-122); Perry and Davies, (OSAR: Quantitative

- 19 -

Structure-Activity Relationships in Drug Design pp. 189-193 Alan R. Liss, Inc. 1989); Lewis and Dean (1989, Proc. R. Soc. Lond. 236:125-140 and 141-162); and, with respect to a model receptor for nucleic acid components, Askew et al. (1989, J. Am. Chem. Soc. 111:1082-1090). Other computer programs that screen and graphically depict chemicals are available from companies such as BioDesign, Inc. (Pasadena, CA.), Allelix, Inc. (Mississauga, Ontario, Canada), and Hypercube, Inc. (Cambridge, Ontario). Although these are primarily designed for application to drugs specific to particular proteins, they can be adapted to design of drugs specific to regions of DNA or RNA, once that region is identified.

Although described above with reference to design and generation of compounds that could alter binding, one can also screen libraries of known compounds, including natural products or synthetic chemicals, and biologically active materials, including proteins, for compounds that are antagonists of MC4-R.

20 Cell-Based Assays

In accordance with the invention, a cell-based assay system can be used to screen for compounds that antagonize the activity of the MC4-R and thereby, modulate addictive behavior. To this end, cells that endogenously express MC4-R can be used to screen for compounds. Alternatively, cell lines, such as 293 cells, COS cells, CHO cells, fibroblasts, and the like, genetically engineered to express the MC4-R can be used for screening purposes. Preferably, host cells genetically engineered to express a functional receptor that responds to activation by melanocortin peptides can be used as an endpoint in the assay (as measured by, e.g., a chemical, physiological, biological, or phenotypic change, induction of a host cell gene or a

- 20 -

reporter gene, change in cAMP levels, adenylyl cyclase activity, host cell G protein activity, extracellular acidification rate, host cell kinase activity, proliferation, differentiation, etc.)

5        In addition, cell-based assay systems can be used to screen for compounds that antagonize the activity of a mutant MC4-R and thereby, modulate addictive behavior. For example, compounds may be identified that increase the activity of mutant MC4-R thereby alleviating the  
10 symptoms of addictive behavior disorders arising from mutant MC4-R. Cell lines, such as 293 cells, COS cells, CHO cells, fibroblasts and the like may be genetically engineered to express mutant receptor. Alternatively, cells that endogenously express mutant MC4 receptor can  
15 be used to screen for compounds.

      To be useful in screening assays that detect receptor activity, the host cells expressing functional MC4-R should give a significant response to MC4-R ligand, preferably greater than 5-fold induction over background.  
20 Host cells should preferably possess a number of characteristics, depending on the readout, to maximize the inductive response by melanocortin peptides, for example, for detecting a strong induction of a cAMP response element (CRE) reporter gene: (a) a low natural  
25 level of cAMP, (b) expression of G proteins capable of interacting with the MC4-R, (c) a high level of adenylyl cyclase, (d) a high level of protein kinase A, (e) a low level of phosphodiesterases, and (f) a high level of cAMP response element binding protein would be advantageous.  
30 To increase response to melanocortin peptide, host cells can be engineered to express a greater amount of favorable factors or a lesser amount of unfavorable factors. In addition, alternative pathways for induction of the CRE reporter could be eliminated to reduce basal  
35 level expression.

- 21 -

In utilizing such cell systems, the cells expressing the melanocortin receptor are exposed to a test compound or to vehicle controls. After exposure, the cells can be assayed to measure the expression and/or 5 activity of components of the signal transduction pathway of the melanocortin receptor. Alternatively, the activity of the signal transduction pathway itself can be assayed. For example, after exposure, cell lysates can be assayed for induction of cAMP. The ability of a test 10 compound to increase levels of cAMP above those levels seen with cells treated with a vehicle control and, preferably, compared to an otherwise identical cell which does not express MC4-R, indicates that the test compound induces signal transduction mediated by the melanocortin 15 receptor expressed by the host cell.

To determine intracellular cAMP concentrations, a scintillation proximity assay (SPA) may be utilized (SPA kit is provided by Amersham Life Sciences, Illinois). The assay utilizes <sup>125</sup>I labeled cAMP, an anti-cAMP 20 antibody, and a scintillant-incorporated microsphere coated with a secondary antibody. When brought into close proximity to the microsphere through the labeled cAMP-antibody complex, <sup>125</sup>I will excite the scintillant to emit light. Unlabeled cAMP extracted from cells competes 25 with the <sup>125</sup>I-labeled cAMP for binding to the antibody and thereby diminishes scintillation. The assay may be performed in 96-well plates to enable high-throughput screening and 96 well-based scintillation counting instruments such as those manufactured by Wallac or 30 Packard may be used for readout.

In screening for compounds that may act as antagonists of MC4-R using receptor activity assays, it is necessary to include ligands that activate the MC4-R, e.g., ( $\alpha$ -MSH, ( $\beta$ -MSH, agouti, ARP or ACTH, to test for

- 22 -

inhibition of signal transduction by the test compound as compared to vehicle controls.

In a specific embodiment of the invention, constructs containing the cAMP responsive element linked 5 to any of a variety of different reporter genes may be introduced into cells expressing the melanocortin receptor. Such reporter genes may include but is not limited to chloramphenicol acetyltransferase (CAT), luciferase, GUS, growth hormone, or placental alkaline 10 phosphatase (SEAP). Following exposure of the cells to the test compound, the level of reporter gene expression may be quantitated to determine the test compound's ability to regulate receptor activity. Alkaline phosphatase assays are particularly useful in the 15 practice of the invention as the enzyme is secreted from the cell. Therefore, tissue culture supernatant may be assayed for secreted alkaline phosphatase. In addition, alkaline phosphatase activity may be measured by calorimetric, bioluminescent or chemilumenscent assays 20 such as those described in Bronstein et al. (1994, Biotechniques 17:172-177). Such assays provide a simple, sensitive easily automatable detection system for pharmaceutical screening.

When it is desired to discriminate between the 25 melanocortin receptors and to identify compounds that selectively agonize or antagonize the MC4-R, the assays described above should be conducted using a panel of host cells, each genetically engineered to express one of the melanocortin receptors (MC1-R through MC5-R). Expression 30 of the human melanocortin receptors is preferred for drug discovery purposes. To this end, host cells can be genetically engineered to express any of the amino acid sequences shown for melanocortin receptors 1 through 5 in FIG. 1. The cloning and characterization of each 35 receptor has been described: MC1-R and MC2-R (Mountjoy,

- 23 -

1992, *Science* 257: 1248-1251; Chhajlani & Wikberg, 1992  
FEBS Lett. 309: 417-420); MC3-R (Roselli-Rehfuss et al.,  
1993, *Proc. Natl. Acad. Sci., USA* 90: 8856-8860; Gantz et  
al., 1993, *J. Biol. Chem.* 268: 8246-8250); MC4-R (Gantz  
5 et al., 1993, *J. Biol. Chem.* 268: 15174-15179; Mountjoy  
et al., 1994, *Mol. Endo.* 8: 1298-1308); and MC5-R  
(Chhajlani et al., 1993, *Biochem. Biophys. Res. Commun.*  
195: 866-873; Gantz et al., 1994, *Biochem. Biophys. Res. Commun.*  
10 *200*; 1214-1220), each of which is incorporated by  
reference herein in its entirety. Thus, each of the  
foregoing sequences can be utilized to engineer a cell or  
cell line that expresses one of the melanocortin  
receptors for use in screening assays described herein.  
To identify compounds that specifically or selectively  
15 regulate MC4-R activity, the activation or inhibition of  
MC4-R activation is compared to the effect of the test  
compound on the other melanocortin receptors.

In a specific embodiment, MC1-R through MC5-R  
cDNAs are expressed in 293 cells under the  
20 transcriptional control of the CMV promoter. Stable cell  
lines are established. Because transfected human MC2-R  
(ACTH-R) did not express very well in 293 cells, the  
human adrenocortical carcinoma cell line H295 (ATCC No.  
CRL-2128), which expresses endogenous ACTH-R, may be used  
25 in screening assays in addition to a stable cell line  
that expresses transfected ACTH-R. In the first round of  
screening, the MC4-R expressing cell line is used to  
identify candidate compounds that activated the MC4-R.  
Once identified, those candidate compounds can be tested  
30 to determine whether they selectively activate the MC4-R.  
The activation of the melanocortin receptors may be  
assayed using, for example, the SPA assay described  
above.

Alternatively, if the host cells express more than  
35 one melanocortin peptide receptor, the background signal

- 24 -

produced by these receptors in response to melanocortin peptides must be "subtracted" from the signal (see Gantz et al., *supra*). The background response produced by these non-MC4-R melanocortin receptors can be determined

5 by a number of methods, including elimination of MC4-R activity by antisense, antibody or antagonist. In this regard, it should be noted that wild type CHO cells demonstrate a small endogenous response to melanocortin peptides which must be subtracted from background.

10 Alternatively, activity contributed from other melanocortin receptors could be eliminated by activating host cells with a MC4-R-specific ligand, or including specific inhibitors of the other melanocortin receptors.

Non-Cell Based Assays

15 In addition to cell based assays, non-cell based assay systems may be used to identify compounds that interact with, e.g., bind to MC4-R. Such compounds may act as antagonists of MC4-R activity and may be used in the treatment of addictive behavior disorders.

20 Since MC4-R is a G protein coupled receptor having seven transmembrane domains, isolated membranes may be used to identify compounds that interact with MC4-R. For example, in a typical experiment using isolated membranes, 293 cells may be genetically engineered to

25 express the MC4-R. Membranes can be harvested by standard techniques and used in an *in vitro* binding assay.  $^{125}$ I-labelled ligand (e.g.,  $^{125}$ I-labelled  $\alpha$ -MSH,  $\beta$ -MSH, or ACTH) is bound to the membranes and assayed for specific activity; specific binding is determined by

30 comparison with binding assays performed in the presence of excess unlabelled ligand.

To identify MC4-R ligands, membranes are incubated with labeled ligand in the presence or absence of test compound. Compounds that bind to the receptor and

- 25 -

compete with labeled ligand for binding to the membranes reduced the signal compared to the vehicle control samples.

Alternatively, soluble MC4-R may be recombinantly expressed and utilized in non-cell based assays to identify compounds that bind to MC4-R. As described above, the recombinantly expressed MC4-R polypeptides or fusion proteins containing one or more of the ECDs of MC4-R can be used in the non-cell based screening assays.

10 Alternatively, peptides corresponding to one or more of the CDs of MC4-R, or fusion proteins containing one or more of the CDs of MC4-R can be used in non-cell based assay systems to identify compounds that bind to the cytoplasmic portion of the MC4-R; such compounds may be

15 useful to antagonize the signal transduction pathway of the MC4-R. In non-cell based assays the recombinantly expressed MC4-R can be attached to a solid substrate such as a test tube, microtitre well or a column, by means well known to those in the art. The test compounds are

20 then assayed for their ability to bind to the MC4-R.

The MC4-R protein and MC4-R ligand used in the present invention can be used in a variety of forms. The proteins can be used in a highly purified form, free of naturally occurring contaminants. Alternatively, a crude

25 preparation containing a mixture of cellular components as well as the target protein can be used. So long as the association of the MC4-R protein with the compound to be tested and/or the MC4-R ligand can be identified in the sample, the MC4-R protein and MC4-R ligand are in a

30 suitable form for use in the above described assay.

Additionally, the MC4-R protein and/or the MC4-R ligand can be modified to contain a detectable label/signal generation system to facilitate detection. Methods for attaching compounds such as fluorescence tags and

- 26 -

secondary labeling compounds such as biotin, are well known in the art.

As indicated above, direct binding to the MC4-R protein or the MC4-R ligand can be used as first step in 5 identifying compounds that antagonize the MC4-R protein. For example, in such methods, compounds are first screened for the ability to bind to either the MC4-R protein or the MC4-R ligand. Compounds that bind MC4-R or the ligand are then screened for the ability to block 10 ligand/receptor interaction, antagonize the MC4-R receptor in an activity assay or the ability to ameliorate an addictive behavior in an animal model, or a combination thereof.

In one aspect of the invention the screens may be 15 designed to identify compounds that antagonize the interaction between MC4-R and MC4-R ligands such as  $\alpha$ -MSH,  $\beta$ -MSH and ACTH. In such screens, the MC4-R ligands are labeled and test compounds can be assayed for their ability to antagonize the binding of labeled ligand to 20 MC4-R.

Such peptides, polypeptides, and fusion proteins can be prepared by recombinant DNA techniques. For example, nucleotide sequences encoding one or more of the four domains of the ECD of the serpentine MC4-R can be 25 synthesized or cloned and ligated together to encode a soluble ECD of the MC4-R. The DNA sequence encoding one or more of the four ECDs (ECD1-4 in FIG. 1) can be ligated together directly or via a linker oligonucleotide that encodes a peptide spacer. Such linkers may encode 30 flexible, glycine-rich amino acid sequences thereby allowing the domains that are strung together to assume a conformation that can bind MC4-R ligands. Alternatively, nucleotide sequences encoding individual domains within the ECD can be used to express MC4-R peptides. In

- 27 -

addition, mutant MC4-R proteins can be expressed by recombinant DNA techniques.

A variety of host-expression vector systems may be utilized to express nucleotide sequences encoding the 5 appropriate regions of the MC4-R to produce such polypeptides. Where the resulting peptide or polypeptide is a soluble derivative (e.g., peptides corresponding to the ECDs; truncated or deleted in which the TMs and/or CDs are deleted) the peptide or polypeptide can be 10 recovered from the culture media. Where the polypeptide or protein is not secreted, the MC4-R product can be recovered from the host cell itself.

The host-expression vector systems also encompass engineered host cells that express the MC4-R or 15 functional equivalents *in situ*, i.e., anchored in the cell membrane. Purification or enrichment of the MC4-R from such expression systems can be accomplished using appropriate detergents and lipid micelles and methods well known to those skilled in the art. However, such 20 engineered host cells themselves may be used in situations where it is important not only to retain the structural and functional characteristics of the MC4-R, but to assess biological activity, e.g., in drug screening assays.

25 The host-expression vector systems that may be used for purposes of the invention include but are not limited to microorganisms such as bacteria (e.g., *E. coli* and *B. subtilis*) transformed with recombinant bacteriophage DNA, plasmid DNA or cosmid DNA expression 30 vectors containing MC4-R nucleotide sequences; yeast (e.g., *Saccharomyces* and *Pichia*) transformed with recombinant yeast expression vectors containing the MC4-R nucleotide sequences; insect cell systems infected with recombinant virus expression vectors (e.g., baculovirus) 35 containing the MC4-R sequences; plant cell systems

- 28 -

infected with recombinant virus expression vectors (e.g., cauliflower mosaic virus, CaMV; tobacco mosaic virus, TMV) or transformed with recombinant plasmid expression vectors (e.g., Ti plasmid) containing MC4-R nucleotide sequences; or mammalian cell systems (e.g., COS, CHO, BHK, 293, 3T3) harboring recombinant expression constructs containing promoters derived from the genome of mammalian cells (e.g., metallothionein promoter) or from mammalian viruses (e.g., the adenovirus late promoter; the vaccinia virus 7.5K promoter).

In bacterial systems, a number of expression vectors may be advantageously selected depending upon the use intended for the MC4-R gene product being expressed. For example, when a large quantity of such a protein is to be produced, for the generation of pharmaceutical compositions of MC4-R protein or for raising antibodies to the MC4-R protein, for example, vectors that direct the expression of high levels of fusion protein products that are readily purified may be desirable. Such vectors include, but are not limited, to the *E. coli* expression vector pUR278 (Ruther et al., 1983, EMBO J. 2:1791), in which the MC4-R coding sequence may be ligated individually into the vector in frame with the lacZ coding region so that a fusion protein is produced; pIN vectors (Inouye & Inouye, 1985, Nucleic Acids Res. 13:3101-3109; Van Heeke & Schuster, 1989, J. Biol. Chem. 264:5503-5509); and the like. pGEX vectors may also be used to express foreign polypeptides as fusion proteins with glutathione S-transferase (GST). In general, such fusion proteins are soluble and can easily be purified from lysed cells by adsorption to glutathione-agarose beads followed by elution in the presence of free glutathione. The PGEX vectors are designed to include thrombin or factor Xa protease cleavage sites so that the

- 29 -

cloned target gene product can be released from the GST moiety.

Alternatively, any fusion protein may be readily purified by utilizing an antibody specific for the fusion 5 protein being expressed. For example, a system described by Janknecht et al. allows for the ready purification of non-denatured fusion proteins expressed in human cell lines (Janknecht et al., 1991, Proc. Natl. Acad. Sci. USA 88: 8972-8976). In this system, the gene of interest is 10 subcloned into a vaccinia recombination plasmid such that the gene's open reading frame is translationally fused to an amino-terminal tag consisting of six histidine residues. Extracts from cells infected with recombinant vaccinia virus are loaded onto Ni<sup>2+</sup>(nitriloacetic acid- 15 agarose columns and histidine-tagged proteins are selectively eluted with imidazole-containing buffers.

In an insect system, *Autographa californica* nuclear polyhedrosis virus (AcNPV) is used as a vector to express foreign genes. The virus grows in *Spodoptera* 20 *frugiperda* cells. The MC4-R coding sequence may be cloned individually into non-essential regions (for example the polyhedrin gene) of the virus and placed under control of an AcNPV promoter (for example the polyhedrin promoter). Successful insertion of MC4-R gene 25 coding sequence will result in inactivation of the polyhedrin gene and production of non-occluded recombinant virus (i.e., virus lacking the proteinaceous coat coded for by the polyhedrin gene). The recombinant viruses are then used to infect cells in which the 30 inserted gene is expressed. (e.g., see Smith et al., 1983, J. Virol. 46: 584; Smith, U.S. Patent No. 4,215,051).

In mammalian host cells, a number of viral-based expression systems may be utilized. In cases where an 35 adenovirus is used as an expression vector, the MC4-R

- 30 -

nucleotide sequence of interest may be ligated to an adenovirus transcription/translation control complex, e.g., the late promoter and tripartite leader sequence. This chimeric gene may then be inserted in the adenovirus 5 genome by *in vitro* or *in vivo* recombination. Insertion in a non-essential region of the viral genome (e.g., region E1 or E3) will result in a recombinant virus that is viable and capable of expressing the MC4-R gene product in infected hosts. (e.g., See Logan & Shenk, 10 1984, Proc. Natl. Acad. Sci. USA 81:3655-3659). Specific initiation signals may also be required for efficient translation of inserted MC4-R nucleotide sequences. These signals include the ATG initiation codon and adjacent sequences. In cases where an entire MC4-R gene 15 or cDNA, including its own initiation codon and adjacent sequences, is inserted into the appropriate expression vector, no additional translational control signals may be needed. However, in cases where only a portion of the MC4-R coding sequence is inserted, exogenous 20 translational control signals, including, perhaps, the ATG initiation codon, must be provided. Furthermore, the initiation codon must be in frame with the reading frame of the desired coding sequence to ensure translation of the entire insert. These exogenous translational control 25 signals and initiation codons can be of a variety of origins, both natural and synthetic. The efficiency of expression may be enhanced by the inclusion of appropriate transcription enhancer elements, transcription terminators, etc. (See Bittner et al., 30 1987, Methods in Enzymol. 153:516-544).

In addition, a host cell strain may be chosen that modulates the expression of the inserted sequences, or modifies and processes the gene product in the specific fashion desired. Such modifications (e.g., 35 glycosylation) and processing (e.g., cleavage) of protein

- 31 -

products may be important for the function of the protein. Different host cells have characteristic and specific mechanisms for the post-translational processing and modification of proteins and gene products.

5 Appropriate cell lines or host systems can be chosen to ensure the correct modification and processing of the foreign protein expressed. Accordingly, eukaryotic host cells that possess the cellular machinery for proper processing of the primary transcript, glycosylation, and  
10 phosphorylation of the gene product may be used. Such mammalian host cells include, but are not limited to, CHO, VERO, BHK, HeLa, COS, 1MDCK, 293, 3T3 and WI38 cell lines.

For long-term, high-yield production of  
15 recombinant proteins, stable expression is preferred. For example, cell lines that stably express the MC4-R sequences described above may be engineered. Rather than using expression vectors that contain viral origins of replication, host cells can be transformed with DNA  
20 controlled by appropriate expression control elements (e.g., promoter, enhancer sequences, transcription terminators, polyadenylation sites, etc.), and a selectable marker. Following the introduction of the foreign DNA, engineered cells may be allowed to grow for  
25 1-2 days in an enriched media, and then are switched to a selective media. The selectable marker in the recombinant plasmid confers resistance to the selection and allows cells to stably integrate the plasmid into their chromosomes and grow to form foci which in turn can  
30 be cloned and expanded into cell lines. This method may advantageously be used to engineer cell lines that express the MC4-R gene product. Such engineered cell lines may be particularly useful in screening and evaluation of compounds that affect the endogenous  
35 activity of the MC4-R gene product.

- 32 -

A number of selection systems may be used, including but not limited to the herpes simplex virus thymidine kinase (Wigler, et al., 1977, Cell 11:223), hypoxanthine-guanine phosphoribosyltransferase (Szybalska & Szybalski, 1962, Proc. Natl. Acad. Sci. USA 48:2026), and adenine phosphoribosyltransferase (Lowy et al., 1980, Cell 22:817) genes can be employed in tk-, hgprt- or aprt- cells, respectively. Also, antimetabolite resistance can be used as the basis of selection for the following genes: dhfr, which confers resistance to methotrexate (Wigler et al., 1980, Natl. Acad. Sci. USA 77:3567; O'Hare et al., 1981, Proc. Natl. Acad. Sci. USA 78:1527); gpt, which confers resistance to mycophenolic acid (Mulligan & Berg, 1981, Proc. Natl. Acad. Sci. USA 78:2072); neo, which confers resistance to the aminoglycoside G-418 (Colberre-Garapin, et al., 1981, J. Mol. Biol. 150:1); and hygro, which confers resistance to hygromycin (Santerre, et al., 1984, Gene 30:147).

Assays For Compounds Or Compositions That Antagonize Expression Of The MC4-R

In addition to assays based on MC4-R protein activity or binding, *in vitro* cell based assays may be designed to screen for compounds that regulate MC4-R expression at either the transcriptional or translational level. Antagonist of the transcription or translation of MC4-R can be used as antagonists of the MC4-R protein e.g. by reducing the amount of MC4-R protein produce by a subject.

In one embodiment, DNA encoding a reporter molecule can be linked to a regulatory element of the MC4-R gene and used in appropriate intact cells, cell extracts or lysates to identify compounds that antagonize MC4-R gene expression. Appropriate cells or cell extracts are prepared from any cell type that normally

- 33 -

expresses the MC4-R gene, thereby ensuring that the cell extracts contain the transcription factors required for *in vitro* or *in vivo* transcription. The screen can be used to identify compounds that antagonize the expression 5 of the reporter construct. In such screens, the level of reporter gene expression is determined in the presence of the test compound and compared to the level of expression in the absence of the test compound.

To identify compounds that regulate MC4-R 10 translation, cells or *in vitro* cell lysates containing MC4-R transcripts may be tested for modulation of MC4-R mRNA translation. To assay for inhibitors of MC4-R translation, test compounds are assayed for their ability to antagonize the translation of MC4-R mRNA in *in vitro* 15 translation extracts.

Compounds that decrease the level of MC4-R expression, either at the transcriptional or translational level, are useful for treatment of addictive behavior disorders.

20 Compounds identified via assays such as those described herein may be useful, for example, in elaborating the biological function of the MC4-R gene product, and for ameliorating addictive behavior disorders. Assays for testing the efficacy of compounds 25 identified in the cellular screen can be tested in art known animal model systems, such as those employed in the Examples, for addictive behavior disorders. For example, animal models may be exposed to a compound, suspected of exhibiting an ability to ameliorate addictive behavior, 30 at a sufficient concentration and for a time sufficient to elicit such an amelioration of addictive behavior in the exposed animals. The response of the animals to the exposure may be monitored by assessing the reversal of the addictive behavior. With regard to intervention, any 35 treatments that reverse any aspect of addictive behavior-

- 34 -

like symptoms should be considered as candidates for human addictive behavior disorder therapeutic intervention.

Uses For Compounds That Antagonize The MC4-R Protein

5 The methods of the present invention are suitable for use in identifying compounds for treating addiction to a wide variety of addictive compounds. Repeated administration to a subject of certain drugs such as cocaine, opiates, alcohol, hallucinogens, minor  
10 tranquilizers, nicotine, and stimulants can lead to physical and/or psychological dependence upon that drug or substance. Although almost any drug is capable of addiction, certain drugs demonstrated a marked propensity to become addictive. These include opiates (opium,  
15 morphine, heroin, and so called "designer drugs," which are opiates that have been chemically modified to avoid literal violation of the controlled substance laws, or to create a better or different psychophysiological effect), methadone, cocaine, nicotine, alcohol, certain  
20 depressants, and certain stimulants. When the drug or substance of abuse is withdrawn from a dependent subject, the subject develops certain symptoms including sleep and mood disturbance and intense craving for the drug or substance of abuse. These symptoms may be collectively  
25 described as a withdrawal syndrome in connection with the present invention. As discussed in the Background, many drugs of addiction have been found to stimulate similar behavior centers of the brain. In the Examples, data show that two classes of addictive compounds, cocaine and  
30 opiates, stimulate similar biological response. Accordingly, compounds identified in the present methods will likely be useful in treating addictive behavior to a wide variety of addictive stimulus. As used herein, the term "addictive disease, disorder, behavior or

- 35 -

addiction" refers to a disease or disorder in which the subject has an extreme craving or compulsion to repeat a particular behavior. The present invention is particularly directed to therapeutic treatment of a drug 5 addiction. Notwithstanding the specifically exemplified ability of the present invention to modulate the biochemistry and behavior that correlate with drug abuse, the invention further extends to the treatment of addictive psychological diseases or disorders, such as, 10 but not limited to, obsessive-compulsive disease.

The methods of the present invention, and the compounds identified using the present methods, are use to treat or prevent an addictive disease or disorder in a subject. Preferably the subject is a human, however, as 15 animals in addition to humans may demonstrate addictive diseases or disorders, whether resulting from addiction to opiates or other drugs subsequent to a veterinary procedure or as a result of a psychological disorder, such as an obsessive compulsive-type of disorder, the 20 invention can be used in birds, such as chickens, turkeys, and pets; in mammals, including but not limited to domesticated animals (canine and feline); farm animals (bovine, ovine, equine, caprine, porcine, and the like); rodents; and undomesticated animals.

25 Administration of Compounds Identified Using the Present Invention

The compounds of the present invention can be provided alone, or in combination with another compound that modulates an addictive behavior. For example, a 30 compound of the present invention used to that reduce heroin addiction can be administered in combination with other anti-addictive compounds. As used herein, two compounds are said to be administered in combination when the two compounds are administered simultaneously or are

- 36 -

administered independently in a fashion such that the compounds will act at the same time.

The compounds identified using the methods of the present invention can be administered via parenteral, 5 subcutaneous, intravenous, intramuscular, intraperitoneal, transdermal, or buccal routes. Alternatively, or concurrently, administration may be by the oral route. The dosage administered will be dependent upon the age, health, and weight of the 10 recipient, kind of concurrent treatment, if any, frequency of treatment, and the nature of the effect desired.

The present invention further provides compositions containing one or more compounds identified 15 using the present invention, in a pharmaceutically acceptable form. While individual needs vary, determination of optimal ranges of effective amounts of each component is within the skill of the art. Typical dosages comprise 0.1 to 100 mg/kg/body wt. The preferred 20 dosages comprise 1 to 100 mg/kg/body wt. The most preferred dosages comprise 10 to 100 mg/kg/body wt.

The phrase "pharmaceutically acceptable" refers to molecular entities and compositions that are physiologically tolerable and do not typically produce an 25 allergic or similar untoward reaction, such as gastric upset, dizziness and the like, when administered to a human. Preferably, as used herein, the term "pharmaceutically acceptable" means approved by a regulatory agency of the Federal or a state government or 30 listed in the U.S. Pharmacopeia or other generally recognized pharmacopeia for use in animals, and more particularly in humans. The term "carrier" refers to a diluent, adjuvant, excipient, or vehicle with which the compound is administered. Such pharmaceutical carriers 35 can be sterile liquids, such as water and oils, including

- 37 -

those of petroleum, animal, vegetable or synthetic origin, such as peanut oil, soybean oil, mineral oil, sesame oil and the like. Water or aqueous solution saline solutions and aqueous dextrose and glycerol 5 solutions are preferably employed as carriers, particularly for injectable solutions. Suitable pharmaceutical carriers are described in "Remington's Pharmaceutical Sciences" by E. W. Martin.

The phrase "therapeutically effective amount" is 10 used herein to mean an amount sufficient to reduce by at least about 15 percent, preferably by at least 50 percent, more preferably by at least 90 percent, and most preferably prevent, a clinically significant deficit in the activity, function and response of the host.

15 Alternatively, a therapeutically effective amount is sufficient to cause an improvement in a clinically significant condition in the host. Preferably, the activity so modified or modulated according to the invention is a behavioral activity. In particular, the 20 behavioral activity may be locomotor activity, conditioned place preference, or drug self-administration.

Without further description, it is believed that 25 one of ordinary skill in the art can, using the preceding description and the following illustrative examples, make and utilize the compounds of the present invention and practice the claimed methods. The following working examples therefore, specifically point out preferred embodiments of the present invention, and are not to be 30 construed as limiting in any way the remainder of the disclosure.

EXAMPLES

The Role Of MC4-R In The Regulation Of Addictive Behavior

The specific role of the MC4-R protein *in vivo* was 35 investigated by:

- 38 -

examining expression patterns of the MC-R family of proteins in rat brain regions involved in addictive behavior (Figures 2 and 3);

examining the changes in mRNA expression levels of 5 rat MC4-R in response to cocaine or morphine administration (Figures 4 and 5);

examining the changes in mRNA expression levels of POMC in response to cocaine administration (Figure 6); examining the changes seen in MSH-Induced grooming

10 behavior in rats caused by the administration of combinations of saline, MSH, and cocaine (Figure 7);

examining changes seen in MSH-induced locomotor activity in rats caused by the administration of combinations of saline, MSH, and cocaine (Figure 8);

15 examining cocaine (10mg/kg) induced locomotor sensitization in Agouti and C57 mice (Figure 9);

examining cocaine (5mg/kg) induced locomotor sensitization in Agouti and C57 mice (Figure 11);

examining cocaine (10mg/kg) induced locomotor 20 sensitization in C57 (wild-type) and MC4-R knockout (homozygous and heterozygous) mice (Figures 12, 13 and 14);

examining cocaine (10mg/kg) induced locomotor sensitization in Rats treated with and without Intra-Nac 25 infusions of SHU9119 (an antagonist of MC4-R) (Figure 15); and

examining cocaine induced place preference in Rats treated with and without Intra-Nac infusions of SHU9119 (an antagonist of MC4-R).

30 All of the results obtained indicate that MC4-R is involved in mediating addictive behavior, particularly in response to cocaine or morphine addiction, and that antagonizing MC4-R results in decreased addictive behavior.

- 39 -

What is claimed is:

1. A method for identifying compounds that regulate addictive behavior, comprising:
  - a) contacting a test compound with a 5 melanocortin 4-receptor (MC4-R),
  - b) determining whether the test compound binds to said MC4-R,
  - c) administering a compound identified as binding to said MC4-R in step (b) to an animal,
  - 10 d) determining whether said compound reduces an addictive behavior, and
  - e) selecting a compound that reduces an addictive behavior in step (d).

2. A method for identifying compounds that regulate addictive behavior, comprising:
  - a) contacting a melanocortin peptide in the presence and absence of a test compound with a melanocortin 4-receptor,
  - b) determining whether the test compound 20 inhibits the binding of the melanocortin peptide to the melanocortin 4-receptor,
  - c) administering a compound identified as inhibiting binding of a melanocortin peptide to said MC4-R in step (b) to an animal,
  - 25 d) determining whether said compound reduces an addictive behavior, and
  - e) selecting a compound that reduces an addictive behavior in step (d).

3. The method of claim 1, wherein said MC4-R is 30 expressed on the surface of a recombinant cell.

- 40 -

4. The method of claim 2, wherein said MC4-R is expressed on the surface of a recombinant cell.

5 5. The method of claim 3, wherein said recombinant cell is an eukaryotic cell.

5 6. The method of claim 4, wherein said recombinant cell is an eukaryotic cell.

7. The method of Claim 4 wherein the inhibition of the binding of the melanocortin peptide to the MC4-R is determined by measuring induction of cAMP in said 10 recombinant cell.

8. The method of Claim 6 wherein the inhibition of the binding of the melanocortin peptide to the MC4-R is determined by measuring induction of cAMP in said recombinant cell.

15 9. The method of Claim 7 in which the cell further contains a reporter gene operatively associated with a cAMP responsive element, and induction of cAMP is indicated by expression of the reporter gene.

10. The method of Claim 8 in which the cell 20 further contains a reporter gene operatively associated with a cAMP responsive element, and induction of cAMP is indicated by expression of the reporter gene.

11. The method of Claim 9 in which the reporter gene is alkaline phosphatase, chloramphenicol 25 acetyltransferase, luciferase, glucuronide synthetase, growth hormone, or placental alkaline phosphatase.

- 41 -

12. The method of Claim 10 in which the reporter gene is alkaline phosphatase, chloramphenicol acetyltransferase, luciferase, glucuronide synthetase, growth hormone, or placental alkaline phosphatase.

5 13. A method for the treatment of addictive behavior disorders, comprising administering an effective amount of a compound that antagonizes the activity of the melanocortin 4-receptor.

14. A pharmaceutical formulation for the  
10 treatment of addictive behavior disorders, comprising a compound that antagonizes the melanocortin 4-receptor, mixed with a pharmaceutically acceptable carrier.

1/16

		EDC 1		50
MC3	MSIQKKYLEG DFVFPVSSSS	FLRTLLEPQL GSALLTAMNA SCCLPSVQPT		
MC4	.....	..... MVNSTHRGM HTSLHLWNRS SYRLHS...		
MC2 (ACTH)	.....	.....		MKH
MC1 ( $\alpha$ -MSH)	.....	.....	..... MAV	QGSQRRLLGS
	51		I	100
MC3	LPNGSEHLQA PFFSNQSSSA	FCEQVFIKPE IFLSLGIVSL LENILVILAV		
MC4	.. NASESLGK GY.... SDGG	CYEQLFVSPE VFVTLGVISL LENILVIVAI		
MC2 (ACTH)	IINSYENINN T.... ARNNS	DCPRVVLPEE IFFTISIVGV LENLIVLAV		
MC1 ( $\alpha$ -MSH)	LNSTPTAIPO	LGLAANQTGA RCLEVSISDG LFLSLGLVSL VENALVVATI		
	101	CD 1	II	150
MC3	VRNGNLHSPM YFFLCSLAVA	DMLVSVSNAL ETIMIAIVHS DYLTFEDQFI		
MC4	AKNKNLHSPM YFFICSLAVA	DMLVSVSNGS ETIIITLLNS T.DTDAQSFT		
MC2 (ACTH)	FKNKNLQAPM YFFICSLAIS	DMLGSLYKIL ENILIIILRNM GYLKPRGSFE		
MC1 ( $\alpha$ -MSH)	AKNRNLHSPM YCFICCLALS	DLLVSGTNVL ETAVILLEA GALVARAAVL		
	151		III	200
MC3	QHMDNIFDSM ICISLVASIC	NLLAIADVRY VTIFYALRYH SIMTVRKALT		
MC4	VNIDNVIDSV ICSSLASIC	SLLSIAVDRY FTIFYALQYH NIMTVKRVGI		
MC2 (ACTH)	TTADDIIDS FVLSLLGSIF	SLSVIAADRY ITIFHALRYH SIVTMRRTVV		
MC1 ( $\alpha$ -MSH)	QQLDNVIDVI TCSSMLSSLC	FLGAIADVRY ISIFYALRYH SIVTLPRARQ		
	201	IV	ECD 3	250
MC3	LIVAIWVCCG VCGVVFIVYS	ESKMVIVCLI TMFFAMMLM GTLYVHMFLL		
MC4	IISCIWAAC VSGILFIIYS	DSSAVIICLI TMFFTMLALM ASLYVHMFLL		
MC2 (ACTH)	VLTVIWTFCT GTGITMVIFS	HHVPTVITFT SLFPLMLVFI LCLYVHMFLL		
MC1 ( $\alpha$ -MSH)	AVAAIWVASV VFSTLFIAYY	DHVAVLLCLV VFFLAMLVLM AVLYVHMLAR		
	251	CD 3	3i	300
MC3	ARLHVVKRIAA LPPADGVAPQ	QHSCMKGAVT ITILLGVFIF CWAPFFLHLV		
MC4	ARLHIKRIAV LPGTGAI..R	QGANMKGAIT LTILIGVFVV CWAPFFLHLI		
MC2 (ACTH)	ARSHTRKIST LPR.....	..ANMKGAIT LTILLGVFIF CWAPFVLHVL		
MC1 ( $\alpha$ -MSH)	ACQHAQGIAR LHKRQ.RPVH	QGFGLKGAVT LTILLGIFFL CWGPFFLHLT		
	301		ECD 4	350
MC3	LIITCPTNPY CICYTAHFNT	YLVLIMCNSV IDPLIYAFRS LELRNTFREI		
MC4	FYISCPQNPY CVCFMSHFNL	YLILIWCNSI IDPLIYALRS QELRKTFKEI		
MC2 (ACTH)	LMTFCPSNPY CACYMSLFQV	NGMLIMCNAV IDPFIYAFRS PELRDAFKKM		
MC1 ( $\alpha$ -MSH)	LIVLCPEHPT CGCIFKNFNL	FLALIICNAI IDPLIYAFHS QELRRTLKEV		
	351			
MC3	LCGCNGMNLG			
MC4	ICCYPLGGLC	DLSSRY		
MC2 (ACTH)	IFCSRYW			
MC1 ( $\alpha$ -MSH)	LTCRW			

FIG. 1

2/16

## REGIONAL DISTRIBUTION OF MC-R mRNA EXPRESSION IN RAT BRAIN


	MC1-R	MC2-R	MC3-R	MC4-R	MC5-R
cortex	-	-	-	+	-/+
hippocampus	-	-	+	+	-/+
olfactory bulb	-	-	-	++	-/+
neostriatum	-	-	-/+	+++	-/+
nucleus accumbens	-	-	-/+	++++	-/+
hypothalamus	-	-	+++	+++	-/+
septum	-	-	++	+++++	nd
periaqueductal gray	-/+	-	+	+++	-/+
ventral tegmentum	-	-	++	++	nd
substantia nigra	-	-	nd	+	-/+
cerebellum	-	-	-	+	-/+

FIG. 2

3/16

## MC4-R mRNA DISTRIBUTION IN BRAIN

194 bp-



marker PC HP SEPT NS HYPO NAc VTA SN PAG CB





FIG. 3


4/16

FIG. 4



5/16

FIG. 5



6/16




FIG. X

7/16




FIG. 7

8/16






FIG. 8

9/16




10/16

FIG. 10




11/16

FIG. 11




12/16

FIG. 12




13/16

FIG. 13



14/16

FIG. 14



15/16

## Cocaine-Induced Locomotor Sensitization in Rat





FIG. 15

16/16



## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US99/19790

## A. CLASSIFICATION OF SUBJECT MATTER

IPC(7) :C07K 14/72, 14/68; G01N 33/566, 33/74, 33/94  
US CL :424/9.2 435/7.2, 7.21, 6, 7.6, 8; 514/2

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 424/9.2 435/7.2, 7.21, 6, 7.6, 8; 514/2

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

WEST, MEDLINE, PHAR, PHIC, PHIN, DRUGNL, DRUGU, CAPLUS  
search terms: melanocortin?, melanocyte stimulating, receptor, addict?, habit?, cocaine, morphin?, duman r, msh? mc4?

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	US 4,649,191 A (HRUBY et al.) 10 March 1987, col. 7, lines 40-49, and col. 11, lines 4 through col. 12, line 5.	1, 3, 5
Y	ALVARO et al. Morphine down-regulates melatocortin-4 receptor expression in brain regions that mediate opiate addiction. Molecular Pharmacology. September 1996, Vol. 50, No. 3, pages 583-591, especially end of column 1 on page 590.	1, 3, 5
Y	ALVARO et al. Melanocortins and opiate addiction. Life Sciences. 30 May 1997, Vol. 61, No. 1, pages 1-9, especially second paragraph of pages 3 and 7.	1, 3, 5

 Further documents are listed in the continuation of Box C.  See patent family annex.

Special categories of cited documents:	
*A*	document defining the general state of the art which is not considered to be of particular relevance
*B*	earlier document published on or after the international filing date
*L*	document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
*O*	document referring to an oral disclosure, use, exhibition or other means
*P*	document published prior to the international filing date but later than the priority date claimed
*T*	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
*X*	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
*Y*	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
*a*	document member of the same patent family

Date of the actual completion of the international search  
24 NOVEMBER 1999

Date of mailing of the international search report

24 JAN 2000

Name and mailing address of the ISA/US  
Commissioner of Patents and Trademarks  
Box PCT  
Washington, D.C. 20231  
Facsimile No. (703) 305-3230

Authorized officer

CLAIRES M. KAUFMAN  
Telephone No. (703) 308-0196

## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US99/19790

## C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	CONTRERAS et al. Antagonism of morphine-induced analgesia, tolerance and dependence by alpha-melanocyte stimulating hormone. J. Pharm. Exp. Ther. 01 April 1984. Vol. 229, Issue 1, page 21, abstract only.	1, 3, 5

**INTERNATIONAL SEARCH REPORT**

International application No.  
PCT/US99/19790

**Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)**

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1.  **Claims Nos.:**  
because they relate to subject matter not required to be searched by this Authority, namely:
  
2.  **Claims Nos.:**  
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
  
3.  **Claims Nos.:**  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

**Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)**

This International Searching Authority found multiple inventions in this international application, as follows:

Please See Extra Sheet.

1.  As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2.  As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3.  As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
  
4.  No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:  
1, 3 and 5

Remark on Protest

The additional search fees were accompanied by the applicant's protest.  
 No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US99/19790

BOX II. OBSERVATIONS WHERE UNITY OF INVENTION WAS LACKING

This ISA found multiple inventions as follows:

Group I, claim(s)1, 3 and 5, drawn to method of identifying compounds that regulate addictive behavior by assaying binding to MC4-R.

Group II, claim(s) 2, 4 and 6-12, drawn to method of identifying compounds that regulate addictive behavior by assaying inhibition of binding of melanocortin peptide to MC4-R.

Group III, claim(s) 13, drawn to method of treating addictive behavior.

Group IV, claim 14, drawn to pharmaceutical formulation of a compound that antagonizes MC4-R.

Pursuant to 37 C.F.R. 1.475(d), this Authority considers that the main invention in the instant application comprises the first-recited invention, that is, the first method. Further, pursuant to 37 C.F.R. 1.475(b)-(d), the ISA/US considers that because MC4-R was old in the art, the inventions do not share a corresponding technical feature, product of group IV and the additional methods of groups II-III do not correspond to the main invention. This Authority therefore considers that the several inventions do not share a special technical feature within the meaning of PCT Rule 13.2 and thus do not relate to a single general inventive concept within the meaning of PCT Rule 13.1.

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>7</sup> :	A1	(11) International Publication Number: <b>WO 00/14115</b>
C07K 14/72, 14/68, G01N 33/566, 33/74, 33/94		(43) International Publication Date: 16 March 2000 (16.03.00)

(21) International Application Number: PCT/US99/19790	(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
(22) International Filing Date: 30 August 1999 (30.08.99)	
(30) Priority Data: 60/099,104 3 September 1998 (03.09.98) US	
(71) Applicant: MILLENNIUM PHARMACEUTICALS, INC. [US/US], 640 Memorial Drive, Cambridge, MA 02139 (US).	
(72) Inventor: DUMAN, Ronald, Guilford, CT 06437 (US).	
(74) Agent: MEIKLEJOHN, Anita, L., Fish & Richardson P.C., 225 Franklin Street, Boston, MA 02110-2804 (US).	
	<b>Published</b> <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>

(54) Title: MC4-R AS TARGET FOR THE IDENTIFICATION OF COMPOUNDS USED TO TREAT DRUG ADDICTION

(57) Abstract

The present invention relates to drug screening assays and therapeutic methods for the treatment of addictive behavior disorders, such as cocaine and morphine addiction utilizing the melanocortin 4-receptor (MC4-R) as the target for intervention. The invention also relates to compounds that antagonize the activity or expression of the MC4-R, and the use of such compounds in the treatment of addictive behavior disorders.

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

- 1 -

MC4-R AS TARGET FOR THE IDENTIFICATION OF COMPOUNDS  
USED TO TREAT DRUG ADDICTION

5

Field of the Invention

The present invention is in the field of drug discovery to treat addictive behavior, particularly drug addiction. The present invention specifically provides drug screening assays and therapeutic methods for the 10 treatment of addictive behavior, particularly drug addiction, involving the melanocortin 4-receptor (MC4-R). The invention also provides novel methods of using antagonists of the activity or expression of MC4-R to treat addictive disorders.

15

Background of the Invention

Drug Addiction

It is well known that the chronic administration of opioids, cocaine and other drugs of abuse results in tolerance and, eventually, dependence. The use of 20 cocaine, opiates, and alcohol are extremely widespread in many countries, despite the well known adverse effects of their use. Drug abuse endures as one of the major public health problems in the United States, and throughout the world. One of the core features of addictive disorders, 25 in laboratory animals as well as in humans, is that drugs of abuse are acutely reinforcing and produce intense drug craving following chronic exposure.

Behavioral and pharmacological studies have implicated the mesolimbic dopamine system (containing the 30 ventral tegmental area [VTA] and its projections, e.g., the nucleus accumbens [NAc]) in the acute reinforcement and craving seen with opiates, cocaine, alcohol, and other drugs of abuse. An important goal of research in this area is to identify changes in this neural pathway 35 that are caused by drugs of abuse and account for the intense craving seen with chronic drug use. Another

- 2 -

critical goal is the identification of factors that can inhibit or reverse these changes to the neural pathway.

Over the past several years, studies have identified a series of common and specific actions of 5 opiates, cocaine, and alcohol on the mesolimbic dopamine system (see, Nestler et al., 1993, *Neuron* 11:995-1006). Different classes of neuronal receptors and neurotransmitters in the brain have been implicated in the complex mechanisms underlying, for example, the 10 addictive effects of opiates. Experimental findings suggest that the opioid, dopaminergic, serotonergic, and benzodiazepine receptor subtypes are involved in addictive effects.

In the VTA, the effects of various drugs of abuse 15 include increased levels of tyrosine hydroxylase (TH) and glial fibrillary acidic protein (GFAP), and decreased levels of neurofilaments. In the NAc, the effects include decreased levels of the inhibitory G protein, Gi alpha, and increased levels of adenylyl cyclase and 20 cyclic AMP-dependent protein kinase. Increasing direct evidence now supports a role for these various biochemical adaptations in the behavioral actions of drugs of abuse mediated via the mesolimbic dopamine system. The finding of increased levels of glial 25 filaments, and reduced levels of neurofilaments, in the VTA suggests that a major form of plasticity, perhaps even neural injury, occurs in this brain region during the course of chronic drug exposure. This possibility is further supported by the observation that chronic 30 morphine or cocaine administration reduces axoplasmic transport, specifically from the VTA to the NA.

Physical dependence or drug addiction to drugs such as narcotics or cocaine has been traditionally treated by drug withdrawal through withholding the drug

- 3 -

from the drug dependent individual, gradually decreasing the amount of drug, particularly with opioids, taken by the individual over time, administering an antagonistic drug, or substituting another drug, such as methadone, 5 buprenorphine, or methadyl acetate, for the drug to ameliorate the physical need for the drug. When a drug is discontinued, withdrawal symptoms appear, the character and severity of which are dependent upon such factors as the particular drug being withdrawn, the daily 10 dose of the drug that is being withdrawn, the duration of use of the drug, and the health of the drug dependent individual.

It is therefore desirable to identify the biological mechanism of drug addiction, and addictive 15 behavior in general, so that better and more effective therapeutic compounds can be identified. The present invention identifies one of the mechanisms of drug addiction and provides methods of identifying compounds for use in treating drug addiction.

20 Melanocortin Receptors

Melanocortins, products of pro-opiomelanocortin (POMC) post-translational processing, are known to have a broad array of physiological actions. Nakanishi et al., Nature 278:423-427 (1979). Aside from their well known 25 effects on adrenal cortical functions (adrenocorticotrophic hormone, ACTH) and on melanocytes (melanocyte stimulating hormone, MSH), melanocortins have been suggested to affect behavior, learning, memory, control of the cardiovascular system, analgesia, 30 thermoregulation, body weight and the release of other neurohumoral agents including prolactin, luteinizing hormone, and biogenic amines. De Wied et al., Methods Achiev. Exp. Pathol. 15:167-199 (1991); De Wied et al., Physiol. Rev. 62:977-1059 (1982); Gruber et al., Am.

- 4 -

J. Physiol. 257:R681-R694 (1989); Murphy et al., Science 210:1247-1249 (1980); Murphy et al., Science 221:192-193 (1983); Ellerkmann et al., Endocrinol. 130:133-138 (1992) and Versteeg et al., Life Sci. 5 38:835-840 (1986). Peripherally, melanocortins have been suggested to have immunomodulatory and neurotrophic properties and to be involved in events surrounding parturition. Cannon et al., J. Immunol. 137:2232-2236 (1986); Gispen, Trends Pharm. Sci. 11:221-222 (1992); 10 Wilson, J. F., Clin. Endocrinol. 17:233-242 (1982); Clark et al., Nature 273:163-164 (1978) and Silman et al., Nature 260:716-718 (1976). Furthermore, melanocortins are present in a myriad of normal human tissues including the brain, adrenal, skin, testis, 15 spleen, kidney, ovary, lung, thyroid, liver, colon, small intestine and pancreas. Tatro et al., Endocrinol. 121:1900-1907 (1987); Mountjoy et al., Science 257:1248-1251 (1992); Chhajlani et al., FEBS Lett. 309:417-420 (1992); Gantz et al. J. Biol. Chem. 268:8246-8250 20 (1993) and Gants et al., J. Biol. Chem. 268:15174-15179 (1993).

Recent studies have described a diversity of subtypes of receptors for the melanocortin peptides and determined that they all belong to the superfamily of 25 seven transmembrane G-protein linked cell surface receptors. Mountjoy et al., Science 257:1248-1251 (1992); Chhajlani et al., FEBS Lett. 309:417-420 (1992); Gantz, Biol. Chem. 268:8246-8250 (1993). In total five receptors have been identified by sequence homology to the 30 first cloned receptor.

The first two melanocortin receptors cloned were the melanocyte MSH receptor, MC1-R, and the adrenocortical ACTH receptor, MC2-R (Mountjoy, Science 257:1248-1251 (1992); Chhajlani & Wikberg, FEBS Lett. 35 309:417-420 (1992)). Subsequently, three additional

- 5 -

melanocortin receptor genes were cloned that recognize the core heptapeptide sequence (MEHFRWG) of melanocortins. Two of these receptors have been shown to be expressed primarily in the brain, MC3-R (Roselli-  
5 Rehfuss et al., Proc. Natl. Acad. Sci. USA 90:8856-8860 (1993); Gantz et al., J. Biol. Chem. 268:8246-8250 (1993)) and MC4-R (Gantz et al., J. Biol. Chem. 268:15174-15179 (1993); Mountjoy et al., Mol. Endo. 8:1298-1308 (1994)). A fifth melanocortin receptor (originally  
10 called MC2-R) is expressed in numerous peripheral organs as well as the brain (Chhajlani et al., Biochem. Biophys. Res. Commun. 195:866-873 (1993); Gantz et al., Biochem. Biophys. Res. Commun. 200:1214-1220 (1994)). The native  
15 ligands and functions of these latter three receptors remains largely unknown.

Recently, the Agouti protein in mice (US Patent No. 5,789,651), and the agouti-related protein in humans (US Patent No. 5,766,877), were shown to be natural ligands for the MC4-R protein. The agouti protein is a  
20 secreted protein expressed in hair follicles and the epidermis, the expression of which correlates with the synthesis of the yellow pigment associated with the agouti phenotype (Miller et al., Gene & Development 7:454-467 1993)). Certain dominant mutations of the  
25 agouti gene result in de-regulated, ubiquitous expression of the agouti protein in mice, demonstrating pleiotropic effects that include obesity and increased tumor susceptibility. (Miller et al., *supra*, (1993); Michaud et al., Genes & Development 7:1203-1213 (1993)). Ectopic  
30 expression of the wild-type agouti protein in transgenic mice results in obesity, diabetes, and the yellow coat color commonly observed in spontaneous obese mutants (Klebig, et al., Proc. Natl. Acad. Sci. USA 92:4728-4732 (1995)). For reviews, see Jackson, *Nature* 362:587-588  
35 (1993); Conklin & Bourne, *Nature* 364:110 (1993);

- 6 -

Siracusa, TIG 10:423-428 (1994); Yen et al., FASEB J. 8:479-488 (1994); Ezzell, J. NIH Res. 6:31-33 (1994); and Manne et al., Proc. Sci. USA 92:4721-4724 (1995). Agouti has been reported to be a competitive antagonist of (MSH 5 binding to the MC1-R and MC4-R in vitro (Lu et al., Nature 371:799-802 (1994)), and the authors speculated that ectopic expression of agouti may lead to obesity by antagonism of melanocortin receptors expressed outside the hair follicle. In this regard, a number of theories 10 have been proposed to account for the induction of obesity by ectopic expression of agouti.

While prior structure-function analyses have been reported in the past on the affinity and potency of the alpha -MSH peptide at the MSH receptor site (for reviews 15 see Peptide Protein Rev 3:1 (1984), The Melanotropic Peptides, Vol. I, II, and III (CRC Press) (1988)), only a few relatively weak antagonists have resulted from these studies [see Int J Peptide Protein Res 35:228 (1990); Peptides 11:351 (1990); and Peptide Res 3:140 (1989)]. 20 However, these papers demonstrate that methods for identifying antagonists of the melanocortin family of receptors is within the skill of the art.

#### Summary of the Invention

The present invention is based on several sets of 25 experiments that includes the observation that mice deficient in the MC4-R protein (MC4-R knockout mice) do not display the addictive effects induced by drugs of addiction, particularly cocaine and morphine. Based on these observations, the present invention provides a 30 novel target for the identification and development of compounds that can be used to treat addictive behavior, particularly drug addiction as well a therapeutic target for treating drug addition.

- 7 -

Specifically, assays are provided (and equivalent assays can be configured) to identify antagonists of the MC4-R receptor protein, in particular receptor binding assays, competition binding assays, activity assays, 5 expression assays (transcription and translation), animal assays and combinations thereof. Such assays result in the identification of compounds that can be used in treating addictive disorders.

It is important to note that assays for 10 identifying antagonists of the MC4-R protein and assays for testing a compound's ability to modulate an addictive behavior in an animal are known in the art.

Brief Description of the Drawings

Figure 1. Deduced amino acid sequences of the 15 melanocortin receptors. The serpentine structure of the melanocortin receptors predicts that the hydrophilic domains located between the TM domains are arranged alternately outside and within the cell to form extracellular domains (ECD; amino acid residues 1-74, 20 137-155, 219-231 and 305-316 in FIG. 1) and cytoplasmic domains (CD; amino acid residues 102-112, 178-197, 251-280 and 339-end in FIG. 1) of the receptor. The predicted transmembrane domains are denoted by overbars and Roman numerals, and the four extracellular domains 25 (ECD1, ECD2, ECD3 and ECD4) and four cytoplasmic domains (CD1, CD2, CD3 and CD4) are indicated.

Figure 2. Regional distribution of MC4-R mRNA expression in the rat brain.

Figure 3. Regional specific expression of MC4-R 30 mRNA in the rat brain

Figure 4. Changes seen in MC4-R mRNA levels in regional centers of the rat brain caused by the administration of cocaine.

- 8 -

Figure 5. Changes seen in MC4-R mRNA levels in the neostriatum of the rat brain caused by the administration of varying doses of morphine.

5 Figure 6. Changes seen in POMC mRNA levels in regional centers of the rat brain caused by the administration of cocaine.

Figure 7. Changes seen in ( $\alpha$ -MSH-induced grooming behavior in rats caused by the administration of combinations of saline (sal), ( $\alpha$ -MSH, and cocaine (coc).

10 Figure 8. Changes seen in ( $\alpha$ -MSH-Induced locomotor activity in rats caused by the administration of combinations of saline (sal), ( $\alpha$ -MSH, and cocaine (coc).

15 Figure 9. Cocaine (10mg/kg) induced locomotor sensitization in Agouti and C57 mice.

Figure 10. Novelty induced locomotor activity in Agouti and C57 mice.

Figure 11. Cocaine (5mg/kg) induced locomotor sensitization in Agouti and C57 (wild-type) mice.

20 Figure 12. Cocaine (10mg/kg) induced locomotor sensitization in C57 (wild-type) and MC4-R knockout (homozygous) mice.

25 Figure 13. Cocaine (10mg/kg) induced locomotor sensitization in C57 (wild-type) and MC4-R knockout (homozygous) mice.

Figure 14. Baseline locomotor activity in C57 (wild-type) and MC4-R knockout (homozygous and heterozygous) mice.

30 Figure 15. Cocaine (10mg/kg) induced locomotor sensitization in rats treated with and without Intra-Nac infusions of SHU9119 (an antagonist of MC4-R).

Figure 16. Cocaine induced place preference in rats treated with and without Intra-Nac infusions of SHU9119 (an antagonist of MC4-R).

- 9 -

Description of the Preferred Embodiments

MC4-R and Addiction

Described below are experiments demonstrating that some of the addictive effects of drugs of addiction 5 (e.g., cocaine and morphine) are potentiated, in part, by the activity of the melanocortin-4 receptor (MC4-R). Mice lacking MC4-R (MC4-R knockout mice) do not demonstrate behavioral responses indicative of drug addiction induced to chronic and acute administration of 10 cocaine or morphine. Based on these observations, one aspect of the present invention provides one of the specific molecular mechanisms that mediates addictive behavior.

As described below, this molecular mechanism can 15 be used: 1) to identify and isolate compounds for treating drug addiction; 2) as a target to rationally design compounds for use in treating drug addiction; and 3) as a therapeutic target for treating drug addiction.

Methods To Identify Compounds For Treating Drug Addiction

20 The present invention provides methods for identifying compounds that can be used to treat drug addiction. These methods are based on identifying antagonists of the melanocortin-4 receptor (MC4-R).

In general, three formats used in drug discovery, 25 cell based systems, cell free systems, and animal based systems, can be adapted for use in the present invention. Further, the assays of the present invention can be configured as binding assays, competitive binding assays or activity-based assays. Lastly, a combination of cell 30 free, cell based, and animal based assays can be used.

Specifically, to identify a therapeutic compound for use in treating drug addiction using a cell based binding assay, a cell expressing a MC4-R protein, a cell expressing a fragment of the MC4-R protein, or a cell 35 expressing a protein containing a fragment of the MC4-R

- 10 -

protein as a fusion protein (hereinafter collectively  $\alpha$  a cell expressing the MC4-R protein $\circ$ ) is incubated in the presence and absence of a compound to be tested. After mixing under conditions that allow association of the 5 MC4-R protein with the compound (if such an interaction will occur), the two mixtures are analyzed and compared to determine if the compound bound to the cell expressing the MC4-R protein. Compounds that bind to cells expressing the MC4-R protein will be identified as a 10 potential antagonist of MC4-R. Preferred potential antagonists do not substantially bind to otherwise identical cells which do not express MC4-R.

To identify a therapeutic compound for use in treating drug addiction using a cell free binding assay, 15 an isolated MC4-R protein, an isolated fragment of the MC4-R protein, or an isolated protein containing a fragment of the MC4-R protein as a fusion protein (hereinafter collectively the MC4-R protein $\circ$ ) is incubated in the presence and absence of a compound to be 20 tested. After mixing under conditions that allow association of the MC4-R protein with the compound (if such an interaction will occur), the two mixtures are analyzed and compared to determine if the compound bound to the MC4-R protein. Compounds that bind to the MC4-R 25 protein will be identified as a potential antagonist of MC4-R.

To identify a therapeutic compound for use in treating drug addiction using a cell based competition binding assay, a cell expressing a MC4-R protein, a cell 30 expressing a fragment of the MC4-R protein, or a cell expressing a protein containing a fragment of the MC4-R protein as a fusion protein (hereinafter collectively  $\alpha$  a cell expressing the MC4-R protein $\circ$ ) is incubated in the presence and absence of a compound to be tested and 35 further in the presence of a ligand of MC4-R. After

- 11 -

mixing under conditions that allow association of the cell expressing the MC4-R protein with the MC4-R ligand, the two mixtures are analyzed and compared to determine if the compound reduced or blocked the binding of the 5 MC4-R ligand to the cell expressing the MC4-R protein. Compounds that reduce or block the binding of the MC4-R ligand to the cell expressing the MC4-R protein will be identified as a potential antagonist of MC4-R.

To identify a therapeutic compound for use in 10 treating drug addiction using a cell-free based competition binding assay, a MC4-R protein, a fragment of the MC4-R protein, or a protein containing a fragment of the MC4-R protein as a fusion protein (hereinafter collectively  $\delta$  a MC4-R protein) is incubated in the 15 presence and absence of a compound to be tested and further in the presence of a ligand of MC4-R. After mixing under conditions that allow association of the MC4-R protein with the MC4-R ligand, the two mixtures are analyzed and compared to determine if the compound 20 reduced or blocked the binding of the MC4-R ligand to the MC4-R protein. Compounds that reduce or block the binding of the MC4-R ligand to the MC4-R protein will be identified as a potential antagonist of MC4-R.

To identify a therapeutic compound for use in 25 treating drug addiction using a cell based activity assay, a cell expressing a MC4-R protein, a cell expressing a functional fragment of the MC4-R protein, or a cell expressing a protein containing a functional fragment of the MC4-R protein as a fusion protein 30 (hereinafter collectively a cell expressing the MC4-R protein) is incubated in the presence and absence of a compound to be tested. After mixing under conditions that allow association of the MC4-R protein with the compound (if such an interaction will occur), the 35 activity of the MC4-R protein is determined in the two

- 12 -

mixtures and compared to determine if the compound antagonized the MC4-R activity in the cell. Compounds that antagonize the activity of the MC4-R protein will be identified as a potential antagonist of MC4-R for use in 5 treating drug addiction. Such activity assays are best performed in the presence of a ligand of MC4-R.

Each of the methods outlined above will be discussed in greater detail below.

The methods of the present invention are suitable 10 for use in identifying compounds for treating addiction to a wide variety of addictive compounds. Repeated administration to a subject of certain drugs such as cocaine, opiates, alcohol, hallucinogens, minor tranquilizers, nicotine, and stimulants can lead to 15 physical and/or psychological dependence upon that drug or substance. Although almost any drug is capable of addiction, certain drugs demonstrated a marked propensity to become addictive. These include opiates (opium, morphine, heroin, and so called "designer drugs," which 20 are opiates that have been chemically modified to avoid literal violation of the controlled substance laws, or to create a better or different psychophysiological effect), methadone, cocaine, nicotine, alcohol, certain depressants, and certain stimulants. When the drug or 25 substance of abuse is withdrawn from a dependent subject, the subject develops certain symptoms including sleep and mood disturbance and intense craving for the drug or substance of abuse. These symptoms may be collectively described as a withdrawal syndrome in connection with the 30 present invention. As discussed in the Background, many drugs of addiction have been found to stimulate similar behavior centers of the brain. Experimental results described in the Examples (below) demonstrate that two classes of addictive compounds, cocaine and opiates, 35 stimulate similar biological response, e.g. increased

- 13 -

MC4-R expression in the nucleus accumbens and neostriatum. Accordingly, compounds identified in the present methods will be useful in treating addictive behavior to a wide variety of addictive stimulus.

5 As used herein, the term "addictive disease, disorder, behavior or addiction" refers to a disease or disorder in which the subject has an extreme craving or compulsion to repeat a particular behavior. The present invention is particularly directed to therapeutic 10 treatment of a drug addiction. Notwithstanding the specifically exemplified ability of the present invention to modulate the biochemistry and behavior that correlate with drug abuse, the invention further extends to the treatment of addictive psychological diseases or 15 disorders, such as, but not limited to, obsessive-compulsive disease.

The methods of the present invention and the compounds identified using the present methods can be used to treat or prevent an addictive disease or disorder 20 in a subject. Preferably the subject is a human, however, as animals in addition to humans may demonstrate addictive diseases or disorders, whether resulting from addiction to opiates or other drugs subsequent to a veterinary procedure or as a result of a psychological 25 disorder, such as an obsessive compulsive-type of disorder, the invention can be used in birds, such as chickens, turkeys, and pets; in mammals, including but not limited to domesticated animals (canine and feline); farm animals (bovine, ovine, equine, caprine, porcine, 30 and the like); rodents; and undomesticated animals.

The MC4-R protein used in the present method can either be the known human MC4-R receptor (Mol. Endocrinol. 8:1298-1308 (1994), US Patent No. 5,703,220, Genbank Accession No. 998457), any allelic variant 35 thereof (Genbank Accession No. 417280 or 136281), or any

- 14 -

ortholog of the human MC4-R protein, such as, but not limited to mouse MC4-R (Genbank Accession No. 3024117) and rat MC4-R (Genbank Accession No. 2494982). Since members of the MC4-R family of proteins display high 5 levels of sequence homology, most members of this family can be used interchangeably in the present methods.

As indicated above, as an alternative to the entire MC4-R protein, a fragment of the MC4-R protein can be used. Such fragments may be selected based on a 10 function, such as the ligand or G-protein binding domain, or can be randomly generated. Preferred fragments will contain the ligand binding domain of the MC4-R protein.

Alternatively, a fusion protein containing the MC4-R protein, or a fragment thereof, can be used. The 15 use of a fusion protein in compound screening assays is well known in the art since fusion protein can aid in configuring such assays, for example with the use of an IgG fusion protein to aid in immobilization.

The MC4-R used in the present method can be any 20 isolated member of the MC4-R ligand family. Examples of MC4-R ligands include human ( $\alpha$ -MSH (FEBS Lett. 135:97-102 (1981), Science 257:543 (1992), Genbank Accession No. P01189), murine ( $\alpha$ -MSH (FEBS Lett. 156:67-71 (1983), Genbank Accession No. P01193), rat ( $\alpha$ -MSH (FEBS Lett. 25 193:54-58 (1985), Genbank Accession No. P01194), the agouti protein (US Patent No. 5,789,651), and the recently clone agouti related protein from humans (US Patent No. 5,766,877).

The assays described herein are intended to 30 identify compounds that affect MC4-R activity. For example, compounds that affect MC4-R activity include but are not limited to compounds that bind to MC4-R, inhibit binding of a natural ligand, block activation, and compounds that bind to the natural ligand of the MC4-R 35 and reduce ligand activity. Compounds that affect MC4-R

- 15 -

gene activity (by affecting MC4-R gene expression, including molecules, e.g., proteins or small organic molecules, that affect transcription or interfere with splicing events so that expression of the full length or 5 the truncated form of the MC4-R can be antagonized) can also be identified using the screen assays of the invention. However, it should be noted that the screening assays described can also identify compounds that antagonize MC4-R signal transduction (e.g., 10 compounds which affect downstream signaling events, such as inhibitors or enhancers of one or more G protein activities which participate in transducing the signal induced by ligand binding to the MC4-R). The identification and use of compounds that affect signaling 15 events downstream of MC4-R and thus modulate effects of MC4-R on the development of addictive behavior disorders are within the scope of the invention.

The compounds that may be screened in accordance with the assays of the invention include, but are not 20 limited to, peptides, antibodies and fragments thereof, and other small molecules or organic compounds that bind to the MC4-R and inhibit the activity triggered by the natural ligand (i.e., antagonists) and peptides, antibodies or fragments thereof, and other small molecule 25 or organic compound that bind to and "neutralize" the natural ligand.

Compounds may include, but are not limited to, peptides such as, for example, soluble peptides, including but not limited to members of random peptide 30 libraries; (see, e.g., Lam et al., 1991, *Nature* 354:82-84; Houghten et al., 1991, *Nature* 354:84-86), and combinatorial chemistry-derived molecular library made of D- and/or L- configuration amino acids, phosphopeptides (including, but not limited to, members of random or 35 partially degenerate, directed phosphopeptide libraries;

- 16 -

see, e.g., Songyang et al., 1993, Cell 72:767-778), antibodies (including, but not limited to, polyclonal, monoclonal, humanized, anti-idiotypic, chimeric or single chain antibodies, and FAb, F(ab()), and FAb expression library fragments, and epitope-binding fragments thereof), and small organic or inorganic molecules.

Other compounds that can be screened in accordance with the invention include, but are not limited to, small organic molecules that are able to cross the blood-brain barrier, gain entry into an appropriate cell and affect the expression of the MC4-R gene or some other gene involved in the MC4-R signal transduction pathway (e.g., by interacting with the regulatory region or transcription factors involved in gene expression) and compounds that affect the activity of the MC4-R or the activity of some other intracellular factor involved in the MC4-R signal transduction pathway, such as, for example, the MC4-R associated G protein.

Computer modeling and searching technologies permit identification of compounds, or the improvement of already identified compounds, that can antagonize MC4-R expression or activity. Having identified such a compound or composition, the active sites or regions are identified. Such active sites might typically be ligand binding sites. The active site can be identified using methods known in the art including, for example, from the amino acid sequences of peptides, from the nucleotide sequences of nucleic acids, or from study of complexes of the relevant compound or composition with its natural ligand. In the latter case, chemical or X-ray crystallographic methods can be used to find the active site by finding where on the factor the complexed ligand is found.

Next, the three dimensional geometric structure of the active site is determined. This can be done by known

- 17 -

methods, including X-ray crystallography, which can determine a complete molecular structure. On the other hand, solid or liquid phase NMR can be used to determine certain intra-molecular distances. Any other

5 experimental method of structure determination can be used to obtain partial or complete geometric structures. The geometric structures may be measured with a complexed ligand, natural or artificial, which may increase the accuracy of the active site structure determined.

10 If an incomplete or insufficiently accurate structure is determined, the methods of computer based numerical modeling can be used to complete the structure or improve its accuracy. Any recognized modeling method may be used, including parameterized models specific to 15 particular biopolymers such as proteins or nucleic acids, molecular dynamics models based on computing molecular motions, statistical mechanics models based on thermal ensembles, or combined models. For most types of models, standard molecular force fields, representing the forces 20 between constituent atoms and groups, are necessary, and can be selected from force fields known in physical chemistry. The incomplete or less accurate experimental structures can serve as constraints on the complete and more accurate structures computed by these modeling 25 methods.

Finally, having determined the structure of the active site, whether experimentally, by modeling, or by a combination, candidate modulating compounds can be identified by searching databases containing compounds 30 along with information on their molecular structure. Such a search seeks compounds having structures that match the determined active site structure and that interact with the groups defining the active site. Such a search can be manual, but is preferably computer assisted. These

- 18 -

compounds found from this search are potential MC4-R antagonizing compounds.

Alternatively, these methods can be used to identify improved antagonizing compounds from an already 5 known antagonizing compound or ligand. The composition of the known compound can be modified and the structural effects of modification can be determined using the experimental and computer modeling methods described above applied to the new composition. The altered 10 structure is then compared to the active site structure of the compound to determine if an improved fit or interaction results. In this manner systematic variations in composition, such as by varying side groups, can be quickly evaluated to obtain modified 15 modulating compounds or ligands of improved specificity or activity.

Further experimental and computer modeling methods useful to identify modulating compounds based upon identification of the active sites of MC4-R and related 20 transduction and transcription factors will be apparent to those of skill in the art.

Examples of molecular modeling systems are the CHARMM and QUANTA programs (Polygen Corporation, Waltham, MA). CHARMM performs the energy minimization and 25 molecular dynamics functions. QUANTA performs the construction, graphic modeling and analysis of molecular structure. QUANTA allows interactive construction, modification, visualization, and analysis of the behavior of molecules with each other.

30 A number of articles review computer modeling of drugs interactive with specific proteins, such as Rotivinen, et al. (1988, Acta Pharmaceutical Fennica 97:159-166); Ripka (1988 New Scientist 54-57); McKinlay and Rossmann (1989, Annu. Rev. Pharmacol. Toxicol. 35 29:111-122); Perry and Davies, (OSAR: Quantitative

- 19 -

Structure-Activity Relationships in Drug Design pp. 189-193 Alan R. Liss, Inc. 1989); Lewis and Dean (1989, Proc. R. Soc. Lond. 236:125-140 and 141-162); and, with respect to a model receptor for nucleic acid components, Askew et al. (1989, J. Am. Chem. Soc. 111:1082-1090). Other computer programs that screen and graphically depict chemicals are available from companies such as BioDesign, Inc. (Pasadena, CA.), Allelix, Inc. (Mississauga, Ontario, Canada), and Hypercube, Inc. (Cambridge, Ontario). Although these are primarily designed for application to drugs specific to particular proteins, they can be adapted to design of drugs specific to regions of DNA or RNA, once that region is identified.

Although described above with reference to design and generation of compounds that could alter binding, one can also screen libraries of known compounds, including natural products or synthetic chemicals, and biologically active materials, including proteins, for compounds that are antagonists of MC4-R.

20 Cell-Based Assays

In accordance with the invention, a cell-based assay system can be used to screen for compounds that antagonize the activity of the MC4-R and thereby, modulate addictive behavior. To this end, cells that endogenously express MC4-R can be used to screen for compounds. Alternatively, cell lines, such as 293 cells, COS cells, CHO cells, fibroblasts, and the like, genetically engineered to express the MC4-R can be used for screening purposes. Preferably, host cells genetically engineered to express a functional receptor that responds to activation by melanocortin peptides can be used as an endpoint in the assay (as measured by, e.g., a chemical, physiological, biological, or phenotypic change, induction of a host cell gene or a

- 20 -

reporter gene, change in cAMP levels, adenylyl cyclase activity, host cell G protein activity, extracellular acidification rate, host cell kinase activity, proliferation, differentiation, etc.)

5 In addition, cell-based assay systems can be used to screen for compounds that antagonize the activity of a mutant MC4-R and thereby, modulate addictive behavior. For example, compounds may be identified that increase the activity of mutant MC4-R thereby alleviating the  
10 symptoms of addictive behavior disorders arising from mutant MC4-R. Cell lines, such as 293 cells, COS cells, CHO cells, fibroblasts and the like may be genetically engineered to express mutant receptor. Alternatively, cells that endogenously express mutant MC4 receptor can  
15 be used to screen for compounds.

To be useful in screening assays that detect receptor activity, the host cells expressing functional MC4-R should give a significant response to MC4-R ligand, preferably greater than 5-fold induction over background.

20 Host cells should preferably possess a number of characteristics, depending on the readout, to maximize the inductive response by melanocortin peptides, for example, for detecting a strong induction of a cAMP response element (CRE) reporter gene: (a) a low natural  
25 level of cAMP, (b) expression of G proteins capable of interacting with the MC4-R, (c) a high level of adenylyl cyclase, (d) a high level of protein kinase A, (e) a low level of phosphodiesterases, and (f) a high level of cAMP response element binding protein would be advantageous.  
30 To increase response to melanocortin peptide, host cells can be engineered to express a greater amount of favorable factors or a lesser amount of unfavorable factors. In addition, alternative pathways for induction of the CRE reporter could be eliminated to reduce basal  
35 level expression.

- 21 -

In utilizing such cell systems, the cells expressing the melanocortin receptor are exposed to a test compound or to vehicle controls. After exposure, the cells can be assayed to measure the expression and/or 5 activity of components of the signal transduction pathway of the melanocortin receptor. Alternatively, the activity of the signal transduction pathway itself can be assayed. For example, after exposure, cell lysates can be assayed for induction of cAMP. The ability of a test 10 compound to increase levels of cAMP above those levels seen with cells treated with a vehicle control and, preferably, compared to an otherwise identical cell which does not express MC4-R, indicates that the test compound 15 induces signal transduction mediated by the melanocortin receptor expressed by the host cell.

To determine intracellular cAMP concentrations, a scintillation proximity assay (SPA) may be utilized (SPA kit is provided by Amersham Life Sciences, Illinois). The assay utilizes <sup>125</sup>I labeled cAMP, an anti-cAMP 20 antibody, and a scintillant-incorporated microsphere coated with a secondary antibody. When brought into close proximity to the microsphere through the labeled cAMP-antibody complex, <sup>125</sup>I will excite the scintillant to emit light. Unlabeled cAMP extracted from cells competes 25 with the <sup>125</sup>I-labeled cAMP for binding to the antibody and thereby diminishes scintillation. The assay may be performed in 96-well plates to enable high-throughput screening and 96 well-based scintillation counting instruments such as those manufactured by Wallac or 30 Packard may be used for readout.

In screening for compounds that may act as antagonists of MC4-R using receptor activity assays, it is necessary to include ligands that activate the MC4-R, e.g., ( $\alpha$ -MSH, ( $\beta$ -MSH, agouti, ARP or ACTH, to test for

- 22 -

inhibition of signal transduction by the test compound as compared to vehicle controls.

In a specific embodiment of the invention, constructs containing the cAMP responsive element linked 5 to any of a variety of different reporter genes may be introduced into cells expressing the melanocortin receptor. Such reporter genes may include but is not limited to chloramphenicol acetyltransferase (CAT), luciferase, GUS, growth hormone, or placental alkaline 10 phosphatase (SEAP). Following exposure of the cells to the test compound, the level of reporter gene expression may be quantitated to determine the test compound's ability to regulate receptor activity. Alkaline phosphatase assays are particularly useful in the 15 practice of the invention as the enzyme is secreted from the cell. Therefore, tissue culture supernatant may be assayed for secreted alkaline phosphatase. In addition, alkaline phosphatase activity may be measured by calorimetric, bioluminescent or chemiluminescent assays 20 such as those described in Bronstein et al. (1994, Biotechniques 17:172-177). Such assays provide a simple, sensitive easily automatable detection system for pharmaceutical screening.

When it is desired to discriminate between the 25 melanocortin receptors and to identify compounds that selectively agonize or antagonize the MC4-R, the assays described above should be conducted using a panel of host cells, each genetically engineered to express one of the melanocortin receptors (MC1-R through MC5-R). Expression 30 of the human melanocortin receptors is preferred for drug discovery purposes. To this end, host cells can be genetically engineered to express any of the amino acid sequences shown for melanocortin receptors 1 through 5 in FIG. 1. The cloning and characterization of each 35 receptor has been described: MC1-R and MC2-R (Mountjoy,

- 23 -

1992, *Science* 257: 1248-1251; Chhajlani & Wikberg, 1992  
FEBS Lett. 309: 417-420); MC3-R (Roselli-Rehfuss et al.,  
1993, *Proc. Natl. Acad. Sci., USA* 90: 8856-8860; Gantz et  
al., 1993, *J. Biol. Chem.* 268: 8246-8250); MC4-R (Gantz  
5 et al., 1993, *J. Biol. Chem.* 268: 15174-15179; Mountjoy  
et al., 1994, *Mol. Endo.* 8: 1298-1308); and MC5-R  
(Chhajlani et al., 1993, *Biochem. Biophys. Res. Commun.*  
195: 866-873; Gantz et al., 1994, *Biochem. Biophys. Res. Commun.*  
Commun. 200: 1214-1220), each of which is incorporated by  
10 reference herein in its entirety. Thus, each of the  
foregoing sequences can be utilized to engineer a cell or  
cell line that expresses one of the melanocortin  
receptors for use in screening assays described herein.  
To identify compounds that specifically or selectively  
15 regulate MC4-R activity, the activation or inhibition of  
MC4-R activation is compared to the effect of the test  
compound on the other melanocortin receptors.

In a specific embodiment, MC1-R through MC5-R  
cDNAs are expressed in 293 cells under the  
20 transcriptional control of the CMV promoter. Stable cell  
lines are established. Because transfected human MC2-R  
(ACTH-R) did not express very well in 293 cells, the  
human adrenocortical carcinoma cell line H295 (ATCC No.  
CRL-2128), which expresses endogenous ACTH-R, may be used  
25 in screening assays in addition to a stable cell line  
that expresses transfected ACTH-R. In the first round of  
screening, the MC4-R expressing cell line is used to  
identify candidate compounds that activated the MC4-R.  
Once identified, those candidate compounds can be tested  
30 to determine whether they selectively activate the MC4-R.  
The activation of the melanocortin receptors may be  
assayed using, for example, the SPA assay described  
above.

Alternatively, if the host cells express more than  
35 one melanocortin peptide receptor, the background signal

- 24 -

produced by these receptors in response to melanocortin peptides must be "subtracted" from the signal (see Gantz et al., *supra*). The background response produced by these non-MC4-R melanocortin receptors can be determined

5 by a number of methods, including elimination of MC4-R activity by antisense, antibody or antagonist. In this regard, it should be noted that wild type CHO cells demonstrate a small endogenous response to melanocortin peptides which must be subtracted from background.

10 Alternatively, activity contributed from other melanocortin receptors could be eliminated by activating host cells with a MC4-R-specific ligand, or including specific inhibitors of the other melanocortin receptors.

Non-Cell Based Assays

15 In addition to cell based assays, non-cell based assay systems may be used to identify compounds that interact with, e.g., bind to MC4-R. Such compounds may act as antagonists of MC4-R activity and may be used in the treatment of addictive behavior disorders.

20 Since MC4-R is a G protein coupled receptor having seven transmembrane domains, isolated membranes may be used to identify compounds that interact with MC4-R. For example, in a typical experiment using isolated membranes, 293 cells may be genetically engineered to

25 express the MC4-R. Membranes can be harvested by standard techniques and used in an *in vitro* binding assay.  $^{125}\text{I}$ -labelled ligand (e.g.,  $^{125}\text{I}$ -labelled  $\alpha$ -MSH,  $\beta$ -MSH, or ACTH) is bound to the membranes and assayed for specific activity; specific binding is determined by

30 comparison with binding assays performed in the presence of excess unlabelled ligand.

To identify MC4-R ligands, membranes are incubated with labeled ligand in the presence or absence of test compound. Compounds that bind to the receptor and

- 25 -

compete with labeled ligand for binding to the membranes reduced the signal compared to the vehicle control samples.

Alternatively, soluble MC4-R may be recombinantly  
5 expressed and utilized in non-cell based assays to identify compounds that bind to MC4-R. As described above, the recombinantly expressed MC4-R polypeptides or fusion proteins containing one or more of the ECDs of MC4-R can be used in the non-cell based screening assays.  
10 Alternatively, peptides corresponding to one or more of the CDs of MC4-R, or fusion proteins containing one or more of the CDs of MC4-R can be used in non-cell based assay systems to identify compounds that bind to the cytoplasmic portion of the MC4-R; such compounds may be  
15 useful to antagonize the signal transduction pathway of the MC4-R. In non-cell based assays the recombinantly expressed MC4-R can be attached to a solid substrate such as a test tube, microtitre well or a column, by means well known to those in the art. The test compounds are  
20 then assayed for their ability to bind to the MC4-R.

The MC4-R protein and MC4-R ligand used in the present invention can be used in a variety of forms. The proteins can be used in a highly purified form, free of naturally occurring contaminants. Alternatively, a crude  
25 preparation containing a mixture of cellular components as well as the target protein can be used. So long as the association of the MC4-R protein with the compound to be tested and/or the MC4-R ligand can be identified in the sample, the MC4-R protein and MC4-R ligand are in a  
30 suitable form for use in the above described assay. Additionally, the MC4-R protein and/or the MC4-R ligand can be modified to contain a detectable label/signal generation system to facilitate detection. Methods for attaching compounds such as florescence tags and

- 26 -

secondary labeling compounds such as biotin, are well known in the art.

As indicated above, direct binding to the MC4-R protein or the MC4-R ligand can be used as first step in 5 identifying compounds that antagonize the MC4-R protein. For example, in such methods, compounds are first screened for the ability to bind to either the MC4-R protein or the MC4-R ligand. Compounds that bind MC4-R or the ligand are then screened for the ability to block 10 ligand/receptor interaction, antagonize the MC4-R receptor in an activity assay or the ability to ameliorate an addictive behavior in an animal model, or a combination thereof.

In one aspect of the invention the screens may be 15 designed to identify compounds that antagonize the interaction between MC4-R and MC4-R ligands such as  $\alpha$ -MSH,  $\beta$ -MSH and ACTH. In such screens, the MC4-R ligands are labeled and test compounds can be assayed for their ability to antagonize the binding of labeled ligand to 20 MC4-R.

Such peptides, polypeptides, and fusion proteins can be prepared by recombinant DNA techniques. For example, nucleotide sequences encoding one or more of the four domains of the ECD of the serpentine MC4-R can be 25 synthesized or cloned and ligated together to encode a soluble ECD of the MC4-R. The DNA sequence encoding one or more of the four ECDs (ECD1-4 in FIG. 1) can be ligated together directly or via a linker oligonucleotide that encodes a peptide spacer. Such linkers may encode 30 flexible, glycine-rich amino acid sequences thereby allowing the domains that are strung together to assume a conformation that can bind MC4-R ligands. Alternatively, nucleotide sequences encoding individual domains within the ECD can be used to express MC4-R peptides. In

- 27 -

addition, mutant MC4-R proteins can be expressed by recombinant DNA techniques.

A variety of host-expression vector systems may be utilized to express nucleotide sequences encoding the 5 appropriate regions of the MC4-R to produce such polypeptides. Where the resulting peptide or polypeptide is a soluble derivative (e.g., peptides corresponding to the ECDs; truncated or deleted in which the TMs and/or CDs are deleted) the peptide or polypeptide can be 10 recovered from the culture media. Where the polypeptide or protein is not secreted, the MC4-R product can be recovered from the host cell itself.

The host-expression vector systems also encompass engineered host cells that express the MC4-R or 15 functional equivalents *in situ*, i.e., anchored in the cell membrane. Purification or enrichment of the MC4-R from such expression systems can be accomplished using appropriate detergents and lipid micelles and methods well known to those skilled in the art. However, such 20 engineered host cells themselves may be used in situations where it is important not only to retain the structural and functional characteristics of the MC4-R, but to assess biological activity, e.g., in drug screening assays.

25 The host-expression vector systems that may be used for purposes of the invention include but are not limited to microorganisms such as bacteria (e.g., *E. coli* and *B. subtilis*) transformed with recombinant bacteriophage DNA, plasmid DNA or cosmid DNA expression 30 vectors containing MC4-R nucleotide sequences; yeast (e.g., *Saccharomyces* and *Pichia*) transformed with recombinant yeast expression vectors containing the MC4-R nucleotide sequences; insect cell systems infected with recombinant virus expression vectors (e.g., baculovirus) 35 containing the MC4-R sequences; plant cell systems

- 28 -

infected with recombinant virus expression vectors (e.g., cauliflower mosaic virus, CaMV; tobacco mosaic virus, TMV) or transformed with recombinant plasmid expression vectors (e.g., Ti plasmid) containing MC4-R nucleotide sequences; or mammalian cell systems (e.g., COS, CHO, BHK, 293, 3T3) harboring recombinant expression constructs containing promoters derived from the genome of mammalian cells (e.g., metallothionein promoter) or from mammalian viruses (e.g., the adenovirus late promoter; the vaccinia virus 7.5K promoter).

In bacterial systems, a number of expression vectors may be advantageously selected depending upon the use intended for the MC4-R gene product being expressed. For example, when a large quantity of such a protein is to be produced, for the generation of pharmaceutical compositions of MC4-R protein or for raising antibodies to the MC4-R protein, for example, vectors that direct the expression of high levels of fusion protein products that are readily purified may be desirable. Such vectors include, but are not limited, to the *E. coli* expression vector pUR278 (Ruther et al., 1983, EMBO J. 2:1791), in which the MC4-R coding sequence may be ligated individually into the vector in frame with the lacZ coding region so that a fusion protein is produced; pIN vectors (Inouye & Inouye, 1985, Nucleic Acids Res. 13:3101-3109; Van Heeke & Schuster, 1989, J. Biol. Chem. 264:5503-5509); and the like. pGEX vectors may also be used to express foreign polypeptides as fusion proteins with glutathione S-transferase (GST). In general, such fusion proteins are soluble and can easily be purified from lysed cells by adsorption to glutathione-agarose beads followed by elution in the presence of free glutathione. The PGEX vectors are designed to include thrombin or factor Xa protease cleavage sites so that the

- 29 -

cloned target gene product can be released from the GST moiety.

Alternatively, any fusion protein may be readily purified by utilizing an antibody specific for the fusion 5 protein being expressed. For example, a system described by Janknecht et al. allows for the ready purification of non-denatured fusion proteins expressed in human cell lines (Janknecht et al., 1991, Proc. Natl. Acad. Sci. USA 88: 8972-8976). In this system, the gene of interest is 10 subcloned into a vaccinia recombination plasmid such that the gene's open reading frame is translationally fused to an amino-terminal tag consisting of six histidine residues. Extracts from cells infected with recombinant vaccinia virus are loaded onto Ni<sup>2+</sup>(nitriloacetic acid- 15 agarose columns and histidine-tagged proteins are selectively eluted with imidazole-containing buffers.

In an insect system, *Autographa californica* nuclear polyhedrosis virus (AcNPV) is used as a vector to express foreign genes. The virus grows in *Spodoptera 20 frugiperda* cells. The MC4-R coding sequence may be cloned individually into non-essential regions (for example the polyhedrin gene) of the virus and placed under control of an AcNPV promoter (for example the polyhedrin promoter). Successful insertion of MC4-R gene 25 coding sequence will result in inactivation of the polyhedrin gene and production of non-occluded recombinant virus (i.e., virus lacking the proteinaceous coat coded for by the polyhedrin gene). The recombinant viruses are then used to infect cells in which the 30 inserted gene is expressed. (e.g., see Smith et al., 1983, J. Virol. 46: 584; Smith, U.S. Patent No. 4,215,051).

In mammalian host cells, a number of viral-based expression systems may be utilized. In cases where an 35 adenovirus is used as an expression vector, the MC4-R

- 30 -

nucleotide sequence of interest may be ligated to an adenovirus transcription/translation control complex, e.g., the late promoter and tripartite leader sequence. This chimeric gene may then be inserted in the adenovirus 5 genome by *in vitro* or *in vivo* recombination. Insertion in a non-essential region of the viral genome (e.g., region E1 or E3) will result in a recombinant virus that is viable and capable of expressing the MC4-R gene product in infected hosts. (e.g., See Logan & Shenk, 10 1984, Proc. Natl. Acad. Sci. USA 81:3655-3659). Specific initiation signals may also be required for efficient translation of inserted MC4-R nucleotide sequences. These signals include the ATG initiation codon and adjacent sequences. In cases where an entire MC4-R gene 15 or cDNA, including its own initiation codon and adjacent sequences, is inserted into the appropriate expression vector, no additional translational control signals may be needed. However, in cases where only a portion of the MC4-R coding sequence is inserted, exogenous 20 translational control signals, including, perhaps, the ATG initiation codon, must be provided. Furthermore, the initiation codon must be in frame with the reading frame of the desired coding sequence to ensure translation of the entire insert. These exogenous translational control 25 signals and initiation codons can be of a variety of origins, both natural and synthetic. The efficiency of expression may be enhanced by the inclusion of appropriate transcription enhancer elements, transcription terminators, etc. (See Bittner et al., 30 1987, Methods in Enzymol. 153:516-544).

In addition, a host cell strain may be chosen that modulates the expression of the inserted sequences, or modifies and processes the gene product in the specific fashion desired. Such modifications (e.g., 35 glycosylation) and processing (e.g., cleavage) of protein

- 31 -

products may be important for the function of the protein. Different host cells have characteristic and specific mechanisms for the post-translational processing and modification of proteins and gene products.

5 Appropriate cell lines or host systems can be chosen to ensure the correct modification and processing of the foreign protein expressed. Accordingly, eukaryotic host cells that possess the cellular machinery for proper processing of the primary transcript, glycosylation, and 10 phosphorylation of the gene product may be used. Such mammalian host cells include, but are not limited to, CHO, VERO, BHK, HeLa, COS, 1MDCK, 293, 3T3 and WI38 cell lines.

For long-term, high-yield production of 15 recombinant proteins, stable expression is preferred. For example, cell lines that stably express the MC4-R sequences described above may be engineered. Rather than using expression vectors that contain viral origins of replication, host cells can be transformed with DNA 20 controlled by appropriate expression control elements (e.g., promoter, enhancer sequences, transcription terminators, polyadenylation sites, etc.), and a selectable marker. Following the introduction of the foreign DNA, engineered cells may be allowed to grow for 25 1-2 days in an enriched media, and then are switched to a selective media. The selectable marker in the recombinant plasmid confers resistance to the selection and allows cells to stably integrate the plasmid into their chromosomes and grow to form foci which in turn can 30 be cloned and expanded into cell lines. This method may advantageously be used to engineer cell lines that express the MC4-R gene product. Such engineered cell lines may be particularly useful in screening and evaluation of compounds that affect the endogenous 35 activity of the MC4-R gene product.

- 32 -

A number of selection systems may be used, including but not limited to the herpes simplex virus thymidine kinase (Wigler, et al., 1977, Cell 11:223), hypoxanthine-guanine phosphoribosyltransferase (Szybalska & Szybalski, 1962, Proc. Natl. Acad. Sci. USA 48:2026), and adenine phosphoribosyltransferase (Lowy et al., 1980, Cell 22:817) genes can be employed in tk-, hgprt- or aprt- cells, respectively. Also, antimetabolite resistance can be used as the basis of selection for the following genes: dhfr, which confers resistance to methotrexate (Wigler et al., 1980, Natl. Acad. Sci. USA 77:3567; O'Hare et al., 1981, Proc. Natl. Acad. Sci. USA 78:1527); gpt, which confers resistance to mycophenolic acid (Mulligan & Berg, 1981, Proc. Natl. Acad. Sci. USA 78:2072); neo, which confers resistance to the aminoglycoside G-418 (Colberre-Garapin, et al., 1981, J. Mol. Biol. 150:1); and hygro, which confers resistance to hygromycin (Santerre, et al., 1984, Gene 30:147).

Assays For Compounds Or Compositions That Antagonize Expression Of The MC4-R

In addition to assays based on MC4-R protein activity or binding, *in vitro* cell based assays may be designed to screen for compounds that regulate MC4-R expression at either the transcriptional or translational level. Antagonist of the transcription or translation of MC4-R can be used as antagonists of the MC4-R protein e.g. by reducing the amount of MC4-R protein produce by a subject.

In one embodiment, DNA encoding a reporter molecule can be linked to a regulatory element of the MC4-R gene and used in appropriate intact cells, cell extracts or lysates to identify compounds that antagonize MC4-R gene expression. Appropriate cells or cell extracts are prepared from any cell type that normally

- 33 -

expresses the MC4-R gene, thereby ensuring that the cell extracts contain the transcription factors required for *in vitro* or *in vivo* transcription. The screen can be used to identify compounds that antagonize the expression 5 of the reporter construct. In such screens, the level of reporter gene expression is determined in the presence of the test compound and compared to the level of expression in the absence of the test compound.

To identify compounds that regulate MC4-R 10 translation, cells or *in vitro* cell lysates containing MC4-R transcripts may be tested for modulation of MC4-R mRNA translation. To assay for inhibitors of MC4-R translation, test compounds are assayed for their ability to antagonize the translation of MC4-R mRNA in *in vitro* 15 translation extracts.

Compounds that decrease the level of MC4-R expression, either at the transcriptional or translational level, are useful for treatment of addictive behavior disorders.

20 Compounds identified via assays such as those described herein may be useful, for example, in elaborating the biological function of the MC4-R gene product, and for ameliorating addictive behavior disorders. Assays for testing the efficacy of compounds 25 identified in the cellular screen can be tested in art known animal model systems, such as those employed in the Examples, for addictive behavior disorders. For example, animal models may be exposed to a compound, suspected of exhibiting an ability to ameliorate addictive behavior, 30 at a sufficient concentration and for a time sufficient to elicit such an amelioration of addictive behavior in the exposed animals. The response of the animals to the exposure may be monitored by assessing the reversal of the addictive behavior. With regard to intervention, any 35 treatments that reverse any aspect of addictive behavior-

- 34 -

like symptoms should be considered as candidates for human addictive behavior disorder therapeutic intervention.

Uses For Compounds That Antagonize The MC4-R Protein

5        The methods of the present invention are suitable for use in identifying compounds for treating addiction to a wide variety of addictive compounds. Repeated administration to a subject of certain drugs such as cocaine, opiates, alcohol, hallucinogens, minor  
10      tranquilizers, nicotine, and stimulants can lead to physical and/or psychological dependence upon that drug or substance. Although almost any drug is capable of addiction, certain drugs demonstrated a marked propensity to become addictive. These include opiates (opium, morphine, heroin, and so called "designer drugs," which are opiates that have been chemically modified to avoid literal violation of the controlled substance laws, or to create a better or different psychophysiological effect), methadone, cocaine, nicotine, alcohol, certain  
15      depressants, and certain stimulants. When the drug or substance of abuse is withdrawn from a dependent subject, the subject develops certain symptoms including sleep and mood disturbance and intense craving for the drug or substance of abuse. These symptoms may be collectively  
20      described as a withdrawal syndrome in connection with the present invention. As discussed in the Background, many drugs of addiction have been found to stimulate similar behavior centers of the brain. In the Examples, data show that two classes of addictive compounds, cocaine and  
25      opiates, stimulate similar biological response.  
30      Accordingly, compounds identified in the present methods will likely be useful in treating addictive behavior to a wide variety of addictive stimulus.      As used herein, the term "addictive disease, disorder, behavior or

- 35 -

addiction" refers to a disease or disorder in which the subject has an extreme craving or compulsion to repeat a particular behavior. The present invention is particularly directed to therapeutic treatment of a drug 5 addiction. Notwithstanding the specifically exemplified ability of the present invention to modulate the biochemistry and behavior that correlate with drug abuse, the invention further extends to the treatment of addictive psychological diseases or disorders, such as, 10 but not limited to, obsessive-compulsive disease.

The methods of the present invention, and the compounds identified using the present methods, are used to treat or prevent an addictive disease or disorder in a subject. Preferably the subject is a human, however, as 15 animals in addition to humans may demonstrate addictive diseases or disorders, whether resulting from addiction to opiates or other drugs subsequent to a veterinary procedure or as a result of a psychological disorder, such as an obsessive compulsive-type of disorder, the 20 invention can be used in birds, such as chickens, turkeys, and pets; in mammals, including but not limited to domesticated animals (canine and feline); farm animals (bovine, ovine, equine, caprine, porcine, and the like); rodents; and undomesticated animals.

25 Administration of Compounds Identified Using the Present Invention

The compounds of the present invention can be provided alone, or in combination with another compound that modulates an addictive behavior. For example, a 30 compound of the present invention used to reduce heroin addiction can be administered in combination with other anti-addictive compounds. As used herein, two compounds are said to be administered in combination when the two compounds are administered simultaneously or are

- 36 -

administered independently in a fashion such that the compounds will act at the same time.

The compounds identified using the methods of the present invention can be administered via parenteral, 5 subcutaneous, intravenous, intramuscular, intraperitoneal, transdermal, or buccal routes. Alternatively, or concurrently, administration may be by the oral route. The dosage administered will be dependent upon the age, health, and weight of the 10 recipient, kind of concurrent treatment, if any, frequency of treatment, and the nature of the effect desired.

The present invention further provides compositions containing one or more compounds identified 15 using the present invention, in a pharmaceutically acceptable form. While individual needs vary, determination of optimal ranges of effective amounts of each component is within the skill of the art. Typical dosages comprise 0.1 to 100 mg/kg/body wt. The preferred 20 dosages comprise 1 to 100 mg/kg/body wt. The most preferred dosages comprise 10 to 100 mg/kg/body wt.

The phrase "pharmaceutically acceptable" refers to molecular entities and compositions that are physiologically tolerable and do not typically produce an 25 allergic or similar untoward reaction, such as gastric upset, dizziness and the like, when administered to a human. Preferably, as used herein, the term "pharmaceutically acceptable" means approved by a regulatory agency of the Federal or a state government or 30 listed in the U.S. Pharmacopeia or other generally recognized pharmacopeia for use in animals, and more particularly in humans. The term "carrier" refers to a diluent, adjuvant, excipient, or vehicle with which the compound is administered. Such pharmaceutical carriers 35 can be sterile liquids, such as water and oils, including

- 37 -

those of petroleum, animal, vegetable or synthetic origin, such as peanut oil, soybean oil, mineral oil, sesame oil and the like. Water or aqueous solution saline solutions and aqueous dextrose and glycerol 5 solutions are preferably employed as carriers, particularly for injectable solutions. Suitable pharmaceutical carriers are described in "Remington's Pharmaceutical Sciences" by E. W. Martin.

The phrase "therapeutically effective amount" is 10 used herein to mean an amount sufficient to reduce by at least about 15 percent, preferably by at least 50 percent, more preferably by at least 90 percent, and most preferably prevent, a clinically significant deficit in the activity, function and response of the host.

15 Alternatively, a therapeutically effective amount is sufficient to cause an improvement in a clinically significant condition in the host. Preferably, the activity so modified or modulated according to the invention is a behavioral activity. In particular, the 20 behavioral activity may be locomotor activity, conditioned place preference, or drug self-administration.

Without further description, it is believed that 25 one of ordinary skill in the art can, using the preceding description and the following illustrative examples, make and utilize the compounds of the present invention and practice the claimed methods. The following working examples therefore, specifically point out preferred embodiments of the present invention, and are not to be 30 construed as limiting in any way the remainder of the disclosure.

EXAMPLES

The Role Of MC4-R In The Regulation Of Addictive Behavior

The specific role of the MC4-R protein *in vivo* was 35 investigated by:

- 38 -

examining expression patterns of the MC-R family of proteins in rat brain regions involved in addictive behavior (Figures 2 and 3);  
examining the changes in mRNA expression levels of 5 rat MC4-R in response to cocaine or morphine administration (Figures 4 and 5);  
examining the changes in mRNA expression levels of POMC in response to cocaine administration (Figure 6);  
examining the changes seen in MSH-Induced grooming 10 behavior in rats caused by the administration of combinations of saline, MSH, and cocaine (Figure 7);  
examining changes seen in MSH-induced locomotor activity in rats caused by the administration of combinations of saline, MSH, and cocaine (Figure 8);  
15 examining cocaine (10mg/kg) induced locomotor sensitization in Agouti and C57 mice (Figure 9);  
examining cocaine (5mg/kg) induced locomotor sensitization in Agouti and C57 mice (Figure 11);  
examining cocaine (10mg/kg) induced locomotor 20 sensitization in C57 (wild-type) and MC4-R knockout (homozygous and heterozygous) mice (Figures 12, 13 and 14);  
examining cocaine (10mg/kg) induced locomotor sensitization in Rats treated with and without Intra-Nac 25 infusions of SHU9119 (an antagonist of MC4-R) (Figure 15); and  
examining cocaine induced place preference in Rats treated with and without Intra-Nac infusions of SHU9119 (an antagonist of MC4-R).  
30 All of the results obtained indicate that MC4-R is involved in mediating addictive behavior, particularly in response to cocaine or morphine addiction, and that antagonizing MC4-R results in decreased addictive behavior.

- 39 -

What is claimed is:

1. A method for identifying compounds that regulate addictive behavior, comprising:
  - a) contacting a test compound with a 5 melanocortin 4-receptor (MC4-R),
  - b) determining whether the test compound binds to said MC4-R,
  - c) administering a compound identified as binding to said MC4-R in step (b) to an animal,
  - 10 d) determining whether said compound reduces an addictive behavior, and
  - e) selecting a compound that reduces an addictive behavior in step (d).

2. A method for identifying compounds that 15 regulate addictive behavior, comprising:

- a) contacting a melanocortin peptide in the presence and absence of a test compound with a melanocortin 4-receptor,
  - b) determining whether the test compound 20 inhibits the binding of the melanocortin peptide to the melanocortin 4-receptor,
  - c) administering a compound identified as inhibiting binding of a melanocortin peptide to said MC4-R in step (b) to an animal,
  - 25 d) determining whether said compound reduces an addictive behavior, and
  - e) selecting a compound that reduces an addictive behavior in step (d).

3. The method of claim 1, wherein said MC4-R is 30 expressed on the surface of a recombinant cell.

- 40 -

4. The method of claim 2, wherein said MC4-R is expressed on the surface of a recombinant cell.

5 5. The method of claim 3, wherein said recombinant cell is an eukaryotic cell.

5 6. The method of claim 4, wherein said recombinant cell is an eukaryotic cell.

7. The method of Claim 4 wherein the inhibition of the binding of the melanocortin peptide to the MC4-R is determined by measuring induction of cAMP in said 10 recombinant cell.

8. The method of Claim 6 wherein the inhibition of the binding of the melanocortin peptide to the MC4-R is determined by measuring induction of cAMP in said recombinant cell.

15 9. The method of Claim 7 in which the cell further contains a reporter gene operatively associated with a cAMP responsive element, and induction of cAMP is indicated by expression of the reporter gene.

10. The method of Claim 8 in which the cell 20 further contains a reporter gene operatively associated with a cAMP responsive element, and induction of cAMP is indicated by expression of the reporter gene.

11. The method of Claim 9 in which the reporter 25 gene is alkaline phosphatase, chloramphenicol acetyltransferase, luciferase, glucuronide synthetase, growth hormone, or placental alkaline phosphatase.

- 41 -

12. The method of Claim 10 in which the reporter gene is alkaline phosphatase, chloramphenicol acetyltransferase, luciferase, glucuronide synthetase, growth hormone, or placental alkaline phosphatase.

5 13. A method for the treatment of addictive behavior disorders, comprising administering an effective amount of a compound that antagonizes the activity of the melanocortin 4-receptor.

14. A pharmaceutical formulation for the  
10 treatment of addictive behavior disorders, comprising a compound that antagonizes the melanocortin 4-receptor, mixed with a pharmaceutically acceptable carrier.

ECD 1

HC3	HSIQKKYLEG DFVFPVSSSS FLRTLLEPOL GSALLTAMNA SCCLPSVQPT	50
HC4	..... MVNSTHRGM HTSLHLWNRs SYRLHS....	
HC2 (ACTH)	.....	HCH
HC1 ( $\alpha$ -MSH)	.....	.HAV QGSQRRLG5

51

HC3	LPNGSEHLQA PFFSNQSSSA FCEQVFIKPE IFLSLGIVSL LENILVILAV	100
HC4	..NASESLCK GY....SDCG CYEQLFVSPPE VFVTLGIVSL LENILVIVAI	
HC2 (ACTH)	IINSYENINN T'....ARNNS DCPRVVLPEE IFFTISIVGV LENLIVLAV	
HC1 ( $\alpha$ -MSH)	LNSTPTAIP0 LGLAANQTA RCLEWSISDG LFLSLGLVSL VENALVVATI	

101 CD 1

HC3	VRNGNLHSPM YFFICSLAVA DHLVSVSNAI ETIHLIAIVS DYLTFEDQF	150
HC4	AKNQNLHSPM YFFICSLAVA DHLVSVSNGS ETIHLITLNS T.DTDAQSF	
HC2 (ACTH)	FKHNQNLQAPM YFFICSLAIS DHLGSLYKIL ENILILRHM GYLPRGSFE	
HC1 ( $\alpha$ -MSH)	AKHRNLHSPM YCFICCLALS DLLVSGTNVL ETAVILLEA GALVARAALV	

151

HC3	OHMDNIFDSH ICISLVASIC NLLAIAVDRY VTIFYALRYH S1MTVRIKALT	200
HC4	VNIDNVIDSV ICSSLLASIC SLLSIAVDRY FTIFYALQYH N1MTVXRVGI	
HC2 (ACTH)	TTADDIIDS LFLVSLLG5IF SLSVIAVDRY ITIFHALRYH S1VHRTVV	
HC1 ( $\alpha$ -MSH)	QQLDNVIDVI TCSSMLLSSLC FLGAIAVDRY ISIFYALRYH S1VTLPRARQ	

201 IV

HC3	LIVAIWVCCG VCGVVFIVYS ESIKIVIVCLI T1FFAHMLM G1LYVHMFLF	250
HC4	IIISCIINACT VSGCILFLIYS DSSAVIICLI T1FFTHMLM ASLYVHMFLM	
HC2 (ACTH)	VLTVIHTFCT CTGITHMVIS H1VPTVITFT SLFPLMFLVFI LCLYVHMFLL	
HC1 ( $\alpha$ -MSH)	AVAAIHWASV VFSTLFIAYY DHVAVLCLV VFFLAMLVLM AVLYVHMFLAR	

251 CD 3

HC3	ARLHVKRIAA LPPADGVAPQ QHSCHRGAVT L1LLGVFIF C1AFFFHLV	300
HC4	ARLHVKRIAV LPGTCAI..R QGANNHKGAI T1LLGVFVV C1AFFFHLI	
HC2 (ACTH)	ARSHTRKIST LPR..... ANHKGAI T1LLGVFIF C1AFFFVLV	
HC1 ( $\alpha$ -MSH)	ACQHAQGIAA LHKRQ.RPVH QGFLGKAVT L1LLG1FFL C1GPFPLHLT	

301 ECD 4

HC3	L11TCPTNPY C1CYTAHFT Y1V1DNCNSV 1DPLIYAFRS LELRNTFRET	350.
HC4	FY1SCPONPY CVCFMHSFNL Y1L11NCNAI 1DPLIYAFRS QELRATFKEI	
HC2 (ACTH)	LNTFCPSNPY CACYHMSLFOV NGH11NCNAV 1DPLIYAFRS PELDAFKHH	
HC1 ( $\alpha$ -MSH)	L1VLCPEKPT CCC1FKNFNL FLALIICNAI 1DPLIYAFRS QELRATLKEV	

351


HC3	LCCGNGMNIG	
HC4	ICCYPLGGLC DLSSRY	
HC2 (ACTH)	IFCSRYW	
HC1 ( $\alpha$ -MSH)	LTC5W	

FIG. 1

## REGIONAL DISTRIBUTION OF MC-R mRNA EXPRESSION IN RAT BRAIN

	MC1-R	MC2-R	MC3-R	MC4-R	MCS-R
cortex	-	-	-	+	-/+
hippocampus	-	-	+	+	-/+
olfactory bulb	-	-	-	++	-/+
neostriatum	-	-	-/+	+++	-/+
nucleus accumbens	-	-	-/+	+++++	-/+
hypothalamus	-	-	+++	+++	-/+
septum	-	-	++	++++++	nd
periaqueductal gray	-/+	-	+	+++	-/+
ventral tegmentum	-	-	++	++	nd
substantia nigra	-	-	nd	+	-/+
cerebellum	-	-	-	+	-/+

Figure 2



**Figure 3**







Figure 4




**Figure 5**



**Figure 6**



**Figure 7**



**Figure 8**

COCAINE (10mg/kg) INDUCED LOCOMOTOR  
SENSITIZATION IN AGOUTI AND C57 MICE






Figure 9

**Figure 10****Figure 11**







Figure 12



**Figure 13**



**Figure 14**



**Figure 15**




Figure 16

## INTERNATIONAL SEARCH REPORT

International application No  
PCT/US99/19790

## A. CLASSIFICATION OF SUBJECT MATTER

IPC(7) :C07K 14/72, 14/68; G01N 33/566, 33/74, 33/94  
US CL :424/9.2 435/7.2, 7.21, 6, 7.6, 8; 514/2

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 424/9.2 435/7.2, 7.21, 6, 7.6, 8; 514/2

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

WEST, MEDLINE, PHAR, PHIC, PHIN, DRUGNL, DRUGU, CAPLUS

search terms: melanocortin?, melanocyte stimulating, receptor, addict?, habit?, cocaine, morphin?, duman r, msh? mc4?

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	US 4,649,191 A (HRUBY et al.) 10 March 1987, col. 7, lines 40-49, and col. 11, lines 4 through col. 12, line 5.	1, 3, 5
Y	ALVARO et al. Morphine down-regulates melatocortin-4 receptor expression in brain regions that mediate opiate addiction. Molecular Pharmacology, September 1996, Vol. 50, No. 3, pages 583-591, especially end of column 1 on page 590.	1, 3, 5
Y	ALVARO et al. Melanocortins and opiate addiction. Life Sciences. 30 May 1997, Vol. 61, No. 1, pages 1-9, especially second paragraph of pages 3 and 7.	1, 3, 5

 Further documents are listed in the continuation of Box C. See patent family annex.

Special categories of cited documents:	
*A*	document defining the general state of the art which is not considered to be of particular relevance
*B*	earlier document published on or after the international filing date
*L*	document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
*O*	document referring to an oral disclosure, use, exhibition or other means
*P*	document published prior to the international filing date but later than the priority date claimed
"T"	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"X"	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"Y"	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"A"	document member of the same patent family

Date of the actual completion of the international search

24 NOVEMBER 1999

Date of mailing of the international search report

24 JAN 2000

Name and mailing address of the ISA/US  
Commissioner of Patents and TrademarksBox PCT  
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

CLAIRES M. KAUFMAN

Telephone No. (703) 308-0196



## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US99/19790

## C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	CONTRERAS et al. Antagonism of morphine-induced analgesia, tolerance and dependence by alpha-melanocyte stimulating hormone. J. Pharm. Exp. Ther. 01 April 1984. Vol. 229, Issue 1, page 21, abstract only.	1, 3, 5

**INTERNATIONAL SEARCH REPORT**

International application No.

PCT/US99/19790

**Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)**

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1.  **Claims Nos.:**  
because they relate to subject matter not required to be searched by this Authority, namely:
  
2.  **Claims Nos.:**  
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
  
3.  **Claims Nos.:**  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

**Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)**

This International Searching Authority found multiple inventions in this international application, as follows:

Please See Extra Sheet.

1.  As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2.  As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3.  As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
  
4.  No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:  
1, 3 and 5

Remark on Protest

The additional search fees were accompanied by the applicant's protest  
 No protest accompanied the payment of additional search fees

INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US99/19790

BOX II OBSERVATIONS WHERE UNITY OF INVENTION WAS LACKING

This ISA found multiple inventions as follows:

Group I, claim(s) 1, 3 and 5, drawn to method of identifying compounds that regulate addictive behavior by assaying binding to MC4-R.

Group II, claim(s) 2, 4 and 6-12, drawn to method of identifying compounds that regulate addictive behavior by assaying inhibition of binding of melanocortin peptide to MC4-R.

Group III, claim(s) 13, drawn to method of treating addictive behavior.

Group IV, claim 14, drawn to pharmaceutical formulation of a compound that antagonizes MC4-R.

Pursuant to 37 C.F.R. 1.475(d), this Authority considers that the main invention in the instant application comprises the first-recited invention, that is, the first method. Further, pursuant to 37 C.F.R. 1.475(b)-(d), the ISA/US considers that because MC4-R was old in the art, the inventions do not share a corresponding technical feature, product of group IV and the additional methods of groups II-III do not correspond to the main invention. This Authority therefore considers that the several inventions do not share a special technical feature within the meaning of PCT Rule 13.2 and thus do not relate to a single general inventive concept within the meaning of PCT Rule 13.1.